Page last updated: 2024-12-06

drospirenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68873
CHEMBL ID1509
CHEBI ID50838
SCHEMBL ID153316
MeSH IDM0107880

Synonyms (121)

Synonym
einecs 266-679-2
drospirenonum [inn-latin]
1,2-dihydro-spirorenone
spiro(17h-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'h)-furan)-3,5'(2h)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6r-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta))-
drospirenone [inn]
zk 30595
6-beta,7-beta;15-beta,16-beta-dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone
brn 4765500
ccris 6523
drospirenona [inn-spanish]
(6r,7r,8r,9s,10r,13s,14s,15s,16s,17s)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13-dimethylspiro-(17h-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'h)-furan)-3,5'(2h)-dione
6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton
zk30595
17-hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone
AB01274783-01
(1r,2r,4r,10r,11s,14s,15s,16s,18s,19s)-10,14-dimethylspiro[hexacyclo[9.8.0.0^{2,4}.0^{5,10}.0^{14,19}.0^{16,18}]nonadecane-15,2'-oxolan]-5-ene-5',7-dione
slynd
gtpl2874
sh-470
zk-30595
drospirenone
drsp
1, 2-dihydrospirorenone
dihydrospirorenone
67392-87-4
slynd (tn)
drospirenone (jan/usp/inn)
D03917
drospirenonum
CHEBI:50838 ,
drospirenona
3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'h,16'h-dicyclopropa[6,7;15,16]-17alpha-pregn-4-ene-21,17-carbolactone
DB01395
1,2-dihydrospirorenone
dehydrospirorenone
6beta,7beta;15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
CHEMBL1509
nsc-760103
nsc 760103
n295j34a25 ,
hsdb 7896
unii-n295j34a25
drospirenone [usan:usp:inn:ban]
dtxcid5026465
cas-67392-87-4
dtxsid7046465 ,
tox21_112216
BCP9000628
BCPP000250
yasmin component drospirenone
yaz component drospirenone
safyral component drospirenone
drospirenone [vandf]
drospirenone [usp-rs]
drospirenone component of yaz
drospirenone [usan]
drospirenone [usp monograph]
drospirenone [jan]
drospirenone [mi]
nextstellis component drospirenone
beyaz component drospirenone
drospirenone component of nextstellis
drospirenone component of beyaz
angeliq component drospirenone
drospirenone component of angeliq
drospirenone component of safyral
drospirenone [mart.]
drospirenone [who-dd]
drospirenone component of yasmin
drospirenone [ep monograph]
drospirenone [orange book]
S1377
AKOS015895237
bdbm150275
us8987239, a
HY-B0111
CS-1863
SCHEMBL153316
D4209
NCGC00164590-02
tox21_112216_1
METQSPRSQINEEU-HXCATZOESA-N
Q-101411
AB01274783_02
mfcd00867350
(1r,2r,4r,10r,11s,14s,15s,16s,18s,19s)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione
sr-01000942231
SR-01000942231-1
drospirenone, united states pharmacopeia (usp) reference standard
drospirenone for peak identification, european pharmacopoeia (ep) reference standard
drospirenone, european pharmacopoeia (ep) reference standard
drospirenone, >=98% (hplc)
6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone
AS-13025
BCP27035
Q419646
BRD-K04394237-001-06-0
EX-A3153
AR-270/43507886
5a,7a-dimethyl-1,1a,3,3',4,4',5,5a,5b,6,7,7a,8a,9,9a,9b,9c,9d-octaadecahydrospiro(cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8,5'-furan)-2',3-dione
CCG-268245
A846434
NCGC00164590-04
6beta,7beta:15beta,16beta -dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone, dihydrospirorenone
drospirenone for peak identification
drospirenone- bio-x
BD166530
EN300-19767634
spiro[8h-cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'(5'h)-furan]-3,5'(4h)-dione, 1,1a,3',4',5,5a,5b,6,7,7a,8a,9,9a,9b,9c,9d-hexadecahydro-5a,7a-dimethyl-, (1ar,5ar,5bs,7as,8s,8as,9a r,9bs,9cr,9dr)-
drospirenone (usp monograph)
drospirenonum (inn-latin)
drospirenona (inn-spanish)
3-oxo-6beta,7beta:15beta,16beta-dimethano-17alpha-pregn-4-ene-21,17-carbolactone
drospirenone (mart.)
drospirenone (ep monograph)
drospirenone (usp-rs)
3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'h,16'h-dicyclopropa(6,7;15,16)-17alpha-pregn-4-ene-21,17-carbolactone
(2's,6r,7r,8r,9s,10r,13s,14s,15s,16s)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-spiro
g03ac10
6-beta,7-beta:15-beta,16-beta-dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone
drospirenone (usan:usp:inn:ban)

Research Excerpts

Overview

Drospirenone (DRSP) is a fourth-generation progestin that interacts with the progesterone receptor (PR) and androgen receptor (AR) in addition to uniquely interacting to the mineralocorticoid receptor (MR) Drospire None (DRS) is an antialdosterone agent with progestogenic and antiandrogenic effects.

ExcerptReferenceRelevance
"Drospirenone (DRSP) is a progestin with antimineralocorticoid and anti-androgenic activity. "( Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women.
Dožić, B; Dožić, I; Srebro, D; Vujović, S; Đogo, A, 2021
)
2.34
"Drospirenone (DRSP) is a fourth-generation progestin that interacts with the progesterone receptor (PR) and androgen receptor (AR) in addition to uniquely interacting to the mineralocorticoid receptor (MR). "( Drospirenone Effects on the Plasminogen Activator System in Immortalized Human Endometrial Endothelial Cells.
Archer, DF; Jacot, T; Sabouni, R, 2021
)
3.51
"Drospirenone (DRO) is a synthetic progestin derived from 17α-spironolactone with a pharmacological mechanism of action similar to progesterone. "( Sex steroids and metabolic responses in mussels Mytilus galloprovincialis exposed to drospirenone.
Bebianno, MJ; Bonastre, M; Cappello, T; Casano, A; Fasulo, S; Fernandes, D; Maisano, M; Mauceri, A; Porte, C, 2017
)
2.12
"Drospirenone (DRS) is a synthetic progestin increasingly used in oral contraceptives with similar effects to progesterone (P4). "( Transcriptional and physiological responses induced by binary mixtures of drospirenone and progesterone in zebrafish (Danio rerio).
Castiglioni, S; Fent, K; Mirbahai, L; Zucchi, S, 2014
)
2.08
"Drospirenone (DRSP) is a progestin with anti-aldosterone properties and it reduces blood pressure in hypertensive women. "( Hormonal therapy with estradiol and drospirenone improves endothelium-dependent vasodilation in the coronary bed of ovariectomized spontaneously hypertensive rats.
Abreu, GR; Almeida, SA; Borgo, MV; Claudio, ER; Gouvea, SA; Graceli, JB; Moysés, MR; Podratz, PL; Romero, WG; Santos, RL; Silva, FB, 2016
)
2.15
"Drospirenone (DRS) is a new synthetic progestin used in contraceptive pills in combination with 17α-ethinylestradiol (EE2)."( Activity of binary mixtures of drospirenone with progesterone and 17α-ethinylestradiol in vitro and in vivo.
Chew, G; Fent, K; Riva, F; Rossier, NM; Zhang, K, 2016
)
1.44
"Drospirenone (DRSP) is an antialdosterone agent with progestogenic and antiandrogenic effects. "( Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women.
Fini, M; Gambacciani, M; Mammi, C; Rosano, GMC; Russo, N; Spoletini, I; Vitale, C; Volterrani, M, 2017
)
2.12
"Drospirenone is a novel progestin that is structurally related to 17 alpha-spirolactone and has antimineralocorticoid and antiandrogenic activity. "( YAZ and the novel progestin drospirenone.
Mishell, DR, 2008
)
2.08
"Drospirenone is a synthetic progestogen contained, with estradiol, in the hormone replacement therapy (HRT) product black triangle downAngeliq (Bayer Schering Pharma). "( Drospirenone in HRT?
, 2009
)
3.24
"Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity that has been developed for hormone therapy as DRSP/17beta-estradiol (DRSP/E2)."( Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women.
Preston, RA, 2009
)
1.07
"Drospirenone (DRSP) is a potent synthetic antimineralocorticoid with progestogenic and antiandrogenic properties, which is widely used for contraception and hormone replacement therapy."( Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome.
Antelmi, A; Caprio, M; Chetrite, G; Fabbri, A; Fève, B; Mammi, C; Marzolla, V; Muscat, A; Zennaro, MC, 2011
)
1.33
"Drospirenone is a novel progestogen that, combined with 17β-estradiol, reduces the frequency and severity of menopausal vasomotor symptoms (VMS) in different populations. "( Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
Chen, SR; Dong, XJ; Lin, JF; Lin, SQ; Qiao, J; Su, H; Sun, LZ; Wang, ML; Wang, SH; Wang, ZH; Xiong, ZA; Xu, YX; Yang, CS; Yang, X; Zhang, LJ; Zhang, YZ; Zhou, YZ; Zhu, J, 2011
)
2.14
"Drospirenone (DRSP) is a contraceptive drug substance with challenging physicochemical properties, due to insufficient solubility in aqueous and oil-based vehicles as well as low chemical stability in aqueous fluids. "( Parenteral oil-based drospirenone microcrystal suspensions-evaluation of physicochemical stability and influence of stabilising agents.
General, S; Nippe, S, 2011
)
2.13
"Drospirenone is a synthetic progestin approved in combination with ethinyl-estradiol as an oral contraceptive (OC)."( Irritable bowel syndrome and drospirenone-containing oral contraceptives; a comparative-safety study.
Bird, ST; Bressler, B; Brophy, JM; Delaney, JA; Etminan, M; Liu, W, 2012
)
1.39
"Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity developed for hormone replacement therapy (HRT) as DRSP/17beta-estradiol (DRSP/ E2)."( Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril.
Alonso, A; Karara, AH; Panzitta, D; Preston, RA; Zhang, P, 2002
)
1.36
"Drospirenone is a new progestogen with antimineralocorticoid and antiandrogenic activity."( Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
Oelkers, W, 2002
)
1.27
"Drospirenone (DRSP) is a novel progestogen derived from 170alpha-spirolactone. "( Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
Rübig, A, 2003
)
3.2
"Drospirenone is a novel progestogen with antimineralocorticoid, progestogenic and antiandrogenic activity."( Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
Keam, SJ; Wagstaff, AJ, 2003
)
1.38
"Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity developed for hormone therapy as DRSP /17-beta estradiol (DRSP/E2). "( Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
Bakris, G; Hanes, V; Norris, PM; Pitt, B; Preston, RA; White, WB, 2005
)
2.16
"Drospirenone (DRSP) is a novel progestin with antimineralocorticoid activity that has been developed for hormone therapy in combination with 17beta-estradiol (E2) in postmenopausal women. "( Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
Hanes, V; Pitt, B; Preston, RA; White, WB, 2005
)
2.07
"Drospirenone is a novel progestogen that possesses antimineralocorticoid activity. "( Added benefits of drospirenone for compliance.
Foidart, JM, 2005
)
2.1
"Drospirenone is a novel progestogen, more closely related to endogenous progesterone in its pharmacological properties than other progestogens available; in combination with estrogen, drospirenone can closely mimic the premenopausal hormonal balance."( Effects of drospirenone/estrogen combinations on bone metabolism.
Christiansen, C, 2005
)
1.44
"Drospirenone is a synthetic progestogen, the only one in hormone replacement therapy in the UK that possesses clinically relevant anti-mineralocorticoid activity."( Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data.
Whitehead, M, 2006
)
1.31
"Drospirenone is a new progestogen in hormone replacement therapy, with anti-mineralocorticoid activity. "( A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity.
Stevenson, JC, 2006
)
1.78
"Drospirenone is a synthetic progestogen with antiandrogenic and antimineralocorticoid effects."( Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Aldrighi, JM; Andrade, RP; Borges, LE; Camargos, AF; Guazelli, C; Isaia, CF; Peixoto, FC; Petracco, A; Yazlle, ME, 2006
)
1.3
"Drospirenone is a unique progestogen derived from 17alpha-spirolactone, with a pharmacologic profile very similar to that of endogenous progesterone. "( Drospirenone and its antialdosterone properties.
Genazzani, AR; Mannella, P; Simoncini, T, 2007
)
3.23
"Drospirenone is a unique progestogen that has clinically been shown to have anti-mineralocorticoid/anti-androgenic effects."( Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?
Motivala, A; Pitt, B, 2007
)
2.5
"Drospirenone is a novel progestin available in combined oral contraceptives and menopausal hormonal therapy. "( Drospirenone: a novel progestin.
Rapkin, AJ; Winer, SA, 2007
)
3.23
"Drospirenone (DRSP) is a progestin that uniquely interferes with the signaling of the mineralocorticoid receptor (MR)."( Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors.
Baldacci, C; Caruso, A; Flamini, MI; Fu, XD; Garibaldi, S; Genazzani, AR; Giretti, MS; Mannella, P; Sanchez, AM; Simoncini, T, 2007
)
2.5
"Drospirenone is a compound closely resembling progesterone, but with the antimineralocorticoid and antiandrogenic properties of a related therapeutic agent, the diuretic, antihypertensive and androgen receptor antagonist, 17alpha-spironolactone."( Drospirenone/ethinyl estradiol.
Rapkin, AJ; Sorger, SN; Winer, SA, 2008
)
2.51
"Drospirenone is a novel progestin under clinical development that is similar to the natural hormone progesterone, combining potent progestogenic with antimineralocorticoid and antiandrogenic activities. "( The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
Fritzemeier, KH; Fuhrmann, U; Krattenmacher, R; Slater, EP, 1996
)
2.06
"Drospirenone is a new synthetic progestogen with both progestational, antimineralocorticoid and antiandrogenic properties. "( Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
Heithecker, R; Helmerhorst, FM; Oelkers, W; Wuttke, W, 2000
)
2.01
"Drospirenone is a novel synthetic progestogen with a pharmacological profile similar to that of natural progesterone. "( A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
Blode, H; Heithecker, R; Loock, W; Röll, G; Wuttke, W, 2000
)
1.98
"Drospirenone is a new progestogen, derived from 17alpha-spirolactone, and the relationship between its progestogenic and its antimineralocorticoid potency is almost identical to that of natural progesterone."( Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
Oelkers, W, 2000
)
2.47
"Drospirenone (DRSP) is a synthetic progestogen which has been developed in combination with ethinylestradiol (EE) for use as an oral contraceptive (Yasmin, Schering AG, Berlin, Germany). "( Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
Blode, H; Foidart, JM; Heithecker, R, 2001
)
2.13

Effects

Drospirenone has been used as a progestin in oral contraceptives with ethinyl estradiol (DRSP/EE) and is expected to regulate endometriosis. The direct effects of drospire None on endometricriosis have not been clarified. Drospire none has a long terminal half-life (about 32 hours), and its bioavailability is about 76%.

ExcerptReferenceRelevance
"Drospirenone has a long terminal half-life (about 32 hours), and its bioavailability is about 76%."( Pharmacology of different progestogens: the special case of drospirenone.
Sitruk-Ware, R, 2005
)
1.29
"Drospirenone has been used as a progestin in oral contraceptives with ethinyl estradiol (DRSP/EE) and is expected to regulate endometriosis, however, the direct effects of drospirenone on endometriosis have not been clarified. "( Drospirenone reduces inflammatory cytokines, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression in human endometriotic stromal cells.
Fujii, T; Harada, M; Hirata, T; Hirota, Y; Izumi, G; Koga, K; Makabe, T; Miyashita, M; Osuga, Y; Sue, F; Taguchi, A; Takamura, M; Takeuchi, A; Urata, Y; Wada-Hiraike, O, 2017
)
3.34
"Drospirenone has a long terminal half-life (about 32 hours), and its bioavailability is about 76%."( Pharmacology of different progestogens: the special case of drospirenone.
Sitruk-Ware, R, 2005
)
1.29

Actions

ExcerptReferenceRelevance
"Drospirenone did not cause EcSC to undergo apoptosis."( Drospirenone induces decidualization in human eutopic endometrial stromal cells and reduces DNA synthesis of human endometriotic stromal cells.
Fujii, T; Harada, M; Hasegawa, A; Hirata, T; Hirota, Y; Izumi, G; Koga, K; Makabe, T; Miyashita, M; Osuga, Y, 2015
)
2.58

Treatment

Drospirenone treatment, however, affected the reproductive success of fathead minnow at concentrations of 6.5 microg/L and higher with a clear dose-response relationship. Treatment with drospire None/EE was associated with elevations in total cholesterol, high-sensitivity C-reactive protein and leptin concentrations.

ExcerptReferenceRelevance
"Drospirenone treatment, however, affected the reproductive success of fathead minnow at concentrations of 6.5 microg/L and higher with a clear dose-response relationship and a NOEC of 0.66 microg/L, which is above environmentally relevant concentrations."( Effects of synthetic gestagens on fish reproduction.
Goller, S; Länge, R; Maser, E; Steger-Hartmann, T; Vonk, R; Zeilinger, J, 2009
)
1.07
"Drospirenone acidic treatment yielded two epimeric lactones by addition of HCl to the 6beta,7beta-cyclopropane ring, namely 7beta-(chloromethyl)-15beta,16beta-methylene-3-oxo-17beta-pregn-4-ene-21,17-carbolactone 4 and 7beta-(chloromethyl)-15beta,16beta-methylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone 5."( Structure elucidation of new compounds from acidic treatment of the progestins gestodene and drospirenone.
Bombieri, G; Colombo, D; Lenna, R; Marchini, N; Modica, E; Scala, A, 2006
)
1.27
"Drospirenone treatment significantly increased beta-endorphin levels in all brain areas analyzed (with the only exception being the parietal lobe), whereas it produced no effect on allopregnanolone levels."( Drospirenone increases central and peripheral beta-endorphin in ovariectomized female rats.
Begliuomini, S; Casarosa, E; Centofanti, M; Freschi, L; Genazzani, AR; Luisi, M; Pieri, M; Pluchino, N,
)
2.3
"Treatment with drospirenone/EE was associated with elevations in total cholesterol, high-sensitivity C-reactive protein and leptin concentrations, whereas treatment with rosiglitazone led to lower triglycerides and higher adiponectin concentrations."( Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
Arslanian, S; Lee, S; Sutton-Tyrrell, K; Tfayli, H; Ulnach, JW, 2011
)
2.15
"Treatment with drospirenone and estradiol also decreased the intensity and severity of sweating, sleep problems, depression, nervousness, and urogenital symptoms."( Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens.
Benda, N; Holler, T; Schürmann, R, 2004
)
1.02

Toxicity

Drospirenone 4 mg film-coated tablet in a dosage regime of 24/4 days is, regarding endometrial histology, a safe drug.

ExcerptReferenceRelevance
" Nonetheless, clinical trials are not usually sufficiently powered to detect rare adverse events such as VTE to enable comparison with other OCs, which could allay fears and concerns about their inherent risks."( Safety of a new oral contraceptive containing drospirenone.
Dinger, J; Heinemann, LA, 2004
)
0.58
" Most adverse events were mild or moderate, with similar rates observed in all groups."( Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens.
Benda, N; Holler, T; Schürmann, R, 2004
)
0.68
"These results demonstrate that the combinations of 1, 2, and 3 mg drospirenone with 1 mg estradiol are safe and effective for the treatment of climacteric symptoms."( Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens.
Benda, N; Holler, T; Schürmann, R, 2004
)
0.92
" There were no significant adverse events, and effects on triglycerides, total cholesterol, and high-density lipoprotein cholesterol were positive."( Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer, DF; Bitterman, P; Foegh, M; Glant, MD; Hanes, V; Kempson, RL; Thorneycroft, IH,
)
0.45
"Results suggest that drospirenone possesses a generally well-accepted side effect profile and resembles comparator oral progestogens in conferring endometrial protection with no significant effect on weight."( A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone.
Shulman, LP, 2006
)
1.03
" Overall, the study drug was well tolerated and adverse events experienced were typical of hormonal contraceptive use."( Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg.
Alincic, S; Cibula, D; Karck, U; Kunz, J; Marr, J; Weidenhammer, HG, 2006
)
0.55
" The commonest adverse event in observation group was breast tenderness which accounted for 12."( [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
Lin, JF; Lin, SQ; Qiao, J; Sun, LZ; Wang, ZH; Xiong, ZA; Xu, YX; Yang, X; Zhang, LJ; Zhou, YZ, 2011
)
0.62
" In the investigational group, the most frequently reported adverse events were acne (16."( Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial.
Bahamondes, L; Darney, P; Kaunitz, AM; Korver, T; Sommer, W; Verhoeven, C; Westhoff, C, 2012
)
0.38
" Improvements in menopausal symptoms (exploratory efficacy variables) were similar in the two groups, while there were fewer women with treatment-related adverse events (18."( One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
Genazzani, AR; Gerlinger, C; Gude, K; Schaefers, M; Schmelter, T, 2013
)
0.61
" DRSP24d, DRSP21d, non-DRSP and levonorgestrel-containing OCs (LNG) showed similar incidence rates of venous and arterial thromboembolism, fatal outcomes, cancer, severe depression and other serious adverse events."( Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
Bardenheuer, K; Dinger, J; Heinemann, K, 2014
)
0.65
"DRSP24d, DRSP21d, non-DRSP and LNG use was associated with similar risks of serious adverse events, and particularly VTE, during routine clinical use."( Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
Bardenheuer, K; Dinger, J; Heinemann, K, 2014
)
0.65
"The 24-day regimen of drospirenone-containing combined OCs is associated with similar risks of venous and arterial thromboembolism, fatal outcomes, cancer, severe depression and other serious adverse events compared to 21-day regimens of drospirenone-containing combined OCs, OCs without drospirenone and LNGs."( Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
Bardenheuer, K; Dinger, J; Heinemann, K, 2014
)
0.96
" The safety variables were adverse events (AE), lab examinations, physical and gynecological examinations, vital signs and body weights and questionnaires."( [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Baihua, D; Caiyan, W; Hongyu, W; Huan, S; Liangdan, T; Meiqing, X; Mulan, R; Qinping, L; Shulan, Z; Wen, D; Xiaomao, L; Xiaoyan, X; Youdi, X; Yufeng, L; Zheng'ai, X; Zhisong, M; Zirong, H; Ziyan, H, 2014
)
0.64
"YAZ is highly effective, acceptable and safe for Chinese women."( [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Baihua, D; Caiyan, W; Hongyu, W; Huan, S; Liangdan, T; Meiqing, X; Mulan, R; Qinping, L; Shulan, Z; Wen, D; Xiaomao, L; Xiaoyan, X; Youdi, X; Yufeng, L; Zheng'ai, X; Zhisong, M; Zirong, H; Ziyan, H, 2014
)
0.64
" The main adverse effects of YAZ included intermenstrual bleeding [13% (12/93) versus 3% (3/94)], menorrhagia [9% (8/93) versus 1% (1/94)], nausea [5% (5/93) versus 4% (4/94)] and skin rash [4% (4/93) versus 2% (2/94)]."( [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
Cheng, W; Fu, Y; Li, L; Mi, W; Sun, L; Wang, J; Xie, S; Zhang, H; Zhang, J, 2014
)
0.64
" The most common adverse effects are intermenstrual bleeding, menorrhagia, nausea and rash."( [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
Cheng, W; Fu, Y; Li, L; Mi, W; Sun, L; Wang, J; Xie, S; Zhang, H; Zhang, J, 2014
)
0.64
" The aim of this study was to evaluate the incidence of TE using the Japanese Adverse Drug Event Report (JADER) database."( Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
Abe, J; Fukuda, A; Hane, Y; Hasegawa, S; Hatahira, H; Hirade, K; Kinosada, Y; Matsui, T; Motooka, Y; Naganuma, M; Nakamura, M; Sasaoka, S; Takahashi, Y, 2017
)
0.46
"5% of the 102 evaluable); two serious adverse events were reported during the Extension Phase (pharyngitis and joint dislocation), neither related to treatment."( Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase.
Apter, D; Colli, E; Gemzell-Danielsson, K; Peters, K, 2020
)
0.79
"0 mg drospirenone over 13 treatment cycles was well tolerated, safe and acceptable for the majority of adolescents."( Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase.
Apter, D; Colli, E; Gemzell-Danielsson, K; Peters, K, 2020
)
1.31
"0 mg oral pills provide a well-tolerated, safe and acceptable contraceptive choice for adolescents."( Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase.
Apter, D; Colli, E; Gemzell-Danielsson, K; Peters, K, 2020
)
0.79
" Four subjects terminated the trial prematurely for the following reasons: on the subject's request (n=2), due to an adverse event (n=1) and due to loss of contact (n=1)."( Safety, influence on the endometrium, sonographic changes and bleeding profile after 13 cycles with the new drospirenone only pill (DOP) for contraception.
Colli, E; Georgiev, D; Koytchev, R; Regidor, PA; Richter, W, 2020
)
0.77
"Drospirenone 4 mg film-coated tablet in a dosage regime of 24/4 days is, regarding endometrial histology, a safe drug."( Safety, influence on the endometrium, sonographic changes and bleeding profile after 13 cycles with the new drospirenone only pill (DOP) for contraception.
Colli, E; Georgiev, D; Koytchev, R; Regidor, PA; Richter, W, 2020
)
2.21
" However, the risk may vary between different adverse drug reaction databases."( Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada.
Kothari, C; Shah, M, 2021
)
0.89
"The purpose of this studty is to examine the safety and risk association between hormonal contraceptive drospirenone and gallbladder diseases using adverse drug reaction database of USFDA's Federal Adverse Events Reporting System (FAERS), Europe's Eudravigilance (EV) and Canada's Canada Vigilance Adverse Reaction Online Database (CVARD)."( Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada.
Kothari, C; Shah, M, 2021
)
1.1
"Individual Case Safety Reports of patients till October 2019 were downloaded from the Federal Adverse Event Reporting System, Eudravigilance, and Canadian database."( Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada.
Kothari, C; Shah, M, 2021
)
0.89
" Large phase 4 studies will be needed to confirm if this combination is associated with an improved adverse event profile or lower thrombosis risk."( Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.
Achilles, SL; Archer, DF; Bouchard, C; Chen, MJ; Creinin, MD; Foidart, JM; Jensen, JT; Kaunitz, AM; Westhoff, CL, 2021
)
1.04
"To detect the signals for drospirenone-containing oral contraceptives (DCOCs) and describe the reporting pattern of adverse events (AEs) caused by DCOCs compared with levonorgestrel/desogestrel/gestodene-containing (second/third generation) oral contraceptives."( Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017.
Choe, SA; Choi, A; Jeon, HL; Lee, Y; Noh, Y; Shin, JY, 2021
)
1.24
"The Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database from 1 February 2008 to 31 December 2017."( Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017.
Choe, SA; Choi, A; Jeon, HL; Lee, Y; Noh, Y; Shin, JY, 2021
)
0.94
" Additionally, we found higher reports of the deaths and vascular AEs associated with DCOCs than with second/third generation oral contraceptives, which warrants careful monitoring to ensure the safe use of DCOCs."( Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017.
Choe, SA; Choi, A; Jeon, HL; Lee, Y; Noh, Y; Shin, JY, 2021
)
0.94
" Other than bleeding complaints and mood disturbance, no adverse event resulted in E4/DRSP discontinuation at rates >1%."( Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.
Achilles, SL; Apolikhina, I; Archer, DF; Bouchard, C; Chen, MJ; Creinin, M; Foidart, JM; Jensen, JT; Jost, M; Kaunitz, AM; Piltonen, T; Suturina, L; Weyers, S; Zatik, J, 2022
)
0.99

Pharmacokinetics

Drospirenone appears to be a viable alternative to the currently available progestogens. The pharmacokinetic characteristics of drospire None and ethinylestradiol have been assessed in healthy female volunteers over a 1 year period.

ExcerptReferenceRelevance
" Based on the biochemical and pharmacodynamic data, drospirenone appears to be a viable alternative to the currently available progestogens."( Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
Krattenmacher, R, 2000
)
2
" The pharmacokinetic characteristics of drospirenone and ethinylestradiol have been assessed in healthy female volunteers over a 1-year period."( A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
Blode, H; Heithecker, R; Loock, W; Röll, G; Wuttke, W, 2000
)
0.8
" The co- administration of EE had no relevant effect on the pharmacokinetic parameters of 3 mg DRSP."( Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women.
Blode, H; Kowal, K; Reif, S; Roth, K, 2012
)
0.7
"3 mg), or placebo provided infrequent serum samples for pharmacokinetic analysis of estradiol and drospirenone, with additional frequent sampling during 24 hours in a study subset."( Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms.
Archer, DF; Gerlinger, C; Gude, K; Schaefers, M; Schmelter, T; Sutter, G, 2014
)
0.86
"A moderate pharmacokinetic drug-drug interaction between DRSP and KTZ was demonstrated in this study."( Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.
Berse, M; Gschwend, S; Höchel, J; Klein, S; Schütt, B; Wiesinger, H; Zollmann, FS, 2015
)
0.64

Compound-Compound Interactions

Study evaluated acceptability, user satisfaction, body weight control and general well-being of estetrol (E4) combined with either drospirenone (DRSP) or levonorgestrel (LNG)

ExcerptReferenceRelevance
"To investigate ovulation inhibition with drospirenone, a novel progestogen that has a profile similar to natural progesterone, when given alone or in combination with ethinylestradiol."( Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol.
Freundl, F; Grillo, M; Heithecker, R; Helmerhorst, FM; Rosenbaum, P; Rossmanith, W; Schmidt, W; Thomas, K; Wolf, A; Wuttke, W, 2000
)
0.83
" The combination with drospirenone had less impact on blood pressure than the combination with desogestrel."( A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
Buicu, C; Endrikat, J; Gaspard, U; Gerlinger, C; Heithecker, R; Lefebvre, P; Scheen, A, 2003
)
0.84
" Treatment groups were given placebo or 1 mg 17beta-estradiol combined with 1, 2 or 3 mg drospirenone daily."( Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
Christiansen, C; Nielsen, T; Ravn, P; Warming, L, 2004
)
0.86
" For postmenopausal HRT, 2 mg drospirenone was combined with 1 mg 17beta-estradiol (Angeliq, Schering AG, Berlin, Germany) for continuous treatment."( Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
Oelkers, WH, 2005
)
2.06
"Three milligrams of DRSP, a progestogen with antimineralocorticoid activity, was combined with either 30 or 20 microg ethinyl estradiol (EE) (DRSP/30EE; DRSP/20EE) and compared with a preparation containing 150 microg desogestrel (DSG) and 30 microg ethinyl estradiol (DSG/30EE)."( A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Endrikat, J; Gerlinger, C; Heithecker, R; Kluft, C; Mulder, SM, 2006
)
0.56
"The present study was conducted to investigate the influence of the strong CYP3A4 inhibitor ketoconazole (KTZ) on the pharmacokinetics of drospirenone (DRSP) administered in combination with ethinylestradiol (EE) or estradiol (E2)."( Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.
Berse, M; Gschwend, S; Höchel, J; Klein, S; Schütt, B; Wiesinger, H; Zollmann, FS, 2015
)
0.84
"A moderate pharmacokinetic drug-drug interaction between DRSP and KTZ was demonstrated in this study."( Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.
Berse, M; Gschwend, S; Höchel, J; Klein, S; Schütt, B; Wiesinger, H; Zollmann, FS, 2015
)
0.64
"The aim of the study was to evaluate the efficacy of different dosages of estetrol (E4) combined with one of two progestins in suppressing the pituitary-ovarian axis and ovulation in healthy premenopausal women."( Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Appels, N; Coelingh Bennink, HJ; Duijkers, IJ; Foidart, JM; Jost, M; Klipping, C; Maillard, C; Mawet, M; Zimmerman, Y, 2015
)
0.65
" This study aimed to compare the different effects of drospirenone (DRP)-containing COCs with cyproterone acetate (CPA)-containing COCs, combined with metformin and lifestyle modifications in women with PCOS and metabolic disorders."( Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016
)
1.04
" Participants took COCs cyclically for 6 months, combined with metformin administration (1."( Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016
)
0.79
"DRP-containing COCs combined with metformin and lifestyle modifications could better control BP and correct carbohydrate metabolism in women with PCOS and metabolic disorders compared with CPA-containing COCs."( Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016
)
0.79
"This study evaluated acceptability, user satisfaction, body weight control and general well-being of estetrol (E4) combined with either drospirenone (DRSP) or levonorgestrel (LNG)."( Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control.
Apter, D; Beekman, L; Coelingh Bennink, HJT; Foidart, JM; Maillard, C; Mawet, M; Zimmerman, Y, 2017
)
0.97
"In this open-label, multi-centre, dose-finding, 6-cycle study, 396 healthy women of reproductive age were randomised into five treatment groups in a 24/4-day regimen: 15 mg or 20 mg E4 combined with either 3 mg DRSP or 150 μg LNG, and as reference estradiol valerate (E2V) combined with dienogest (DNG)."( Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control.
Apter, D; Beekman, L; Coelingh Bennink, HJT; Foidart, JM; Maillard, C; Mawet, M; Zimmerman, Y, 2017
)
0.77
"The present study shows that 15 mg estetrol combined with 3 mg DRSP is associated with a high-user acceptability and satisfaction, and with a favourable body weight control."( Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control.
Apter, D; Beekman, L; Coelingh Bennink, HJT; Foidart, JM; Maillard, C; Mawet, M; Zimmerman, Y, 2017
)
0.77
"There are no previous data on the influence of drospirenone (DRSP) in combination with estradiol (E2) on the breast in postmenopausal women."( Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells-A prospective randomized trial.
Brismar, K; Hirschberg, AL; Lundström, E; Tani, E, 2019
)
1.16
"5 mg of NETA in continuous combination with 1 mg of oral E2."( Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells-A prospective randomized trial.
Brismar, K; Hirschberg, AL; Lundström, E; Tani, E, 2019
)
0.9
"This was a Phase I, open-label, two cohort (n=18/cohort), fixed-sequence study in healthy females that evaluated the drug-drug interaction (DDI) between multiple-dose ATV+COBI or DRV+COBI and single-dose drospirenone/ethinyl estradiol (EE)."( Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Das, M; Kearney, BP; Ling, KH; Majeed, SR; West, S, 2019
)
0.7

Bioavailability

Drospirenone has a long terminal half-life (about 32 hours) and its bioavailability is about 76%.

ExcerptReferenceRelevance
" Drospirenone has a long terminal half-life (about 32 hours), and its bioavailability is about 76%."( Pharmacology of different progestogens: the special case of drospirenone.
Sitruk-Ware, R, 2005
)
1.48
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" The study was conducted to investigate the relative bioavailability and pharmacokinetic parameters of EE and drsp after oral administration of EE-betadex clathrate/drsp."( Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Benda, N; Blode, H; Schürmann, R, 2008
)
0.54
"The relative bioavailability of EE and drsp after EE-betadex clathrate/drsp tablet administration was comparable with that achieved with the EE/drsp tablet (107% and 101%, respectively)."( Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Benda, N; Blode, H; Schürmann, R, 2008
)
0.54
"The betadex clathrate formulation of EE, when combined with DRSP, does not affect the pharmacokinetics and relative bioavailability of either EE or drsp."( Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Benda, N; Blode, H; Schürmann, R, 2008
)
0.54
"The bioavailability of EE and drospirenone was similar after administration of EE/drospirenone/levomefolate calcium and EE/drospirenone."( Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.
Blode, H; Diefenbach, K; Eydeler, U; Richard, F; Rohde, B; Trummer, D; Wiesinger, H, 2012
)
0.88
" The biological actions of progestins are primarily determined by their interactions with steroid receptors, and factors such as metabolism, pharmacokinetics, bioavailability and the regulation of endogenous steroid hormone biosynthesis are often overlooked."( Fourth-Generation Progestins Inhibit 3β-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids.
Africander, D; Louw-du Toit, R; Perkins, MS; Snoep, JL; Storbeck, KH, 2016
)
0.43
" However, unfavourable bioavailability limits its clinical use."( Contraceptive drugs mitigate experimental stroke-induced brain injury.
Binder, N; El Amki, M; Imthurn, B; Luft, AR; Merki-Feld, GS; Schneider, H; Steffen, R; Wegener, S; Weller, M, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Doses were scaled from human doses to account for differences in bioavailability and body weight, and OCs were administered daily via oral gavage for 4 rat estrous cycles (20 days)."( The Effect of Oral Contraceptive Hormones on Anterior Cruciate Ligament Strength.
Chang, W; Dragoo, JL; Hsue, L; Konopka, JA; Thio, T, 2020
)
0.56
"Open label, single centre, two-treatment, two-sequence, crossover study in 24 healthy female volunteers, with duration of 1 day per sequence and with a real wash-out period of 14 days to investigate the relative bioavailability of DRSP with both forms of administration."( Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial.
Colli, E; Kirkov, V; Koytchev, R; Regidor, PA; Richter, WH, 2022
)
1

Dosage Studied

Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation. The hazard ratio (HR) from Cox proportional hazards models was used to assess the VTE relative risk.

ExcerptRelevanceReference
" It is also a progestogen that suppresses ovulation in normal women at a daily dosage of 2 mg."( Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women.
Bähr, V; Beier, S; Berger, V; Bolik, A; Elger, W; Hazard, B; Heithecker, A; Oelkers, W, 1991
)
0.28
" There have been dramatic dosage reductions of both the estrogen and progestogen components and various progestogens have been introduced over time."( Yasmin: the reason why.
Thorneycroft, IH, 2002
)
0.31
" At a dosage that suppresses ovulation, drospirenone induces mild natriuresis, which is followed by compensatory stimulation of the RAAS (comparable to a low sodium diet)."( Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
Oelkers, W, 2002
)
0.81
"Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation that combines in a novel dosing regimen the lowest dosage of ethinyl estradiol commonly used today with drospirenone, an innovative progestin."( Drospirenone/ethinyl estradiol.
Rapkin, AJ; Sorger, SN; Winer, SA, 2008
)
3.23
"This study was conducted to compare ovarian activity of an oral contraceptive containing drospirenone (drsp) 3 mg plus ethinylestradiol (EE) 20 mcg administered in 24/4 regimen compared with the conventional 21/7 regimen, during intended use and following predefined dosing errors."( Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
Duijkers, I; Klipping, C; Marr, J; Trummer, D, 2008
)
0.84
"The drsp 3 mg/EE 20 mcg oral contraceptive in a 24/4 regimen was associated with greater ovarian suppression (despite intentional dosing error), which results in decreased hormonal fluctuations, and may increase contraceptive efficacy with the low-dose formulation."( Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
Duijkers, I; Klipping, C; Marr, J; Trummer, D, 2008
)
0.62
"The aim of this study was to investigate the pharmacokinetics of injectable conventional dosage forms containing steroids."( Evaluation of the in vitro release and pharmacokinetics of parenteral injectable formulations for steroids.
General, S; Nippe, S; Preuße, C, 2013
)
0.39
" The hazard ratio (HR) from Cox proportional hazards models was used to assess the VTE relative risk (RR) with drospirenone compared with levonorgestrel, adjusted by a propensity score used to control for baseline co-morbidity and stratified by EE dosage and user-type (new/current)."( Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG, 2013
)
2.04
"Combined with a progestin, E4 adequately suppresses ovarian activity, particularly when given at a dosage above 10 mg/day."( Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Appels, N; Coelingh Bennink, HJ; Duijkers, IJ; Foidart, JM; Jost, M; Klipping, C; Maillard, C; Mawet, M; Zimmerman, Y, 2015
)
0.65
" The flexible extended dosing regimen, containing drospirenone and ethinylestradiol, may be particularly useful in patients suffering severe dysmenorrhea and improving the adherence and compliance with treatment."( Advances in pharmacotherapy for treating endometriosis.
Alessandri, F; Bogliolo, S; Ferrero, S; Gardella, B; Grillo, F; Leone Roberti Maggiore, U; Mastracci, L; Tafi, E; Vellone, VG, 2015
)
0.67
" A marketed dosing regimen of estradiol valerate with dienogest (E2V/DNG) served as reference since it contains (like E4) a natural oestrogen."( Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA).
Apter, D; Beekman, L; Coelingh Bennink, HJ; Foidart, JM; Maillard, C; Mawet, M; Zimmerman, Y, 2016
)
0.43
"Background Combined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and/or progestin type."( Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.
Adeyanju, OA; Olatunji, LA, 2019
)
1.96
"Drospirenone 4 mg film-coated tablet in a dosage regime of 24/4 days is, regarding endometrial histology, a safe drug."( Safety, influence on the endometrium, sonographic changes and bleeding profile after 13 cycles with the new drospirenone only pill (DOP) for contraception.
Colli, E; Georgiev, D; Koytchev, R; Regidor, PA; Richter, W, 2020
)
2.21
" It is composed of drospirenone (DRSP) at a dosage of 4 mg in a regimen 24/4."( Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime.
Colli, E; Palacios, S; Regidor, PA, 2020
)
1.11
"This review focuses on the pharmacological and inhibition of the ovulation of progestin-only, estrogen-free contraceptive containing drospirenone in a dosage of 4 mg in a regimen 24/4."( Drospirenone 4 mg in a 24/4 regimen maintains inhibition of ovulation even after a 24-h delay pill intake - Pharmacological aspects and comparison to other progestin-only pills.
Colli, E; Regidor, PA, 2022
)
2.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
contraceptive drugA chemical substance that prevents or reduces the probability of conception.
aldosterone antagonistnull
progestinA synthetic progestogen.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
steroid lactone
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency10.81050.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency14.45780.173734.304761.8120AID1346859; AID1346924
PPM1D proteinHomo sapiens (human)Potency20.82120.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency14.45780.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency7.95690.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency11.29570.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency9.09830.000221.22318,912.5098AID1259381; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
progesterone receptorHomo sapiens (human)Potency0.02270.000417.946075.1148AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.82070.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.89960.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.18920.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency5.35380.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency28.25020.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency1.77830.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.28530.000229.305416,493.5996AID743069; AID743075; AID743079
GVesicular stomatitis virusPotency23.91850.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency27.81820.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency18.85240.001024.504861.6448AID743212; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency10.68220.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency2.66010.023723.228263.5986AID743222
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency15.84890.10009.191631.6228AID1346983
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency22.42090.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.48890.000627.21521,122.0200AID743202
Interferon betaHomo sapiens (human)Potency21.99050.00339.158239.8107AID1347407; AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency29.84930.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency29.84930.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)37.90000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)16.40000.11007.190310.0000AID1473738
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (99)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347054Inhibition of BCRP-mediated mitoxantrone efflux in human myeloid leukemia PLB985 cells measured by flow cytometry2017SLAS discovery : advancing life sciences R & D, 01, Volume: 22, Issue:1
Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1473884Drug concentration at steady state in human at 3 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473885Ratio of drug concentration at steady state in human at 3 mg, po after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473886Ratio of drug concentration at steady state in human at 3 mg, po after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473883AUC in human at 3 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1346902Human Mineralocorticoid receptor (3C. 3-Ketosteroid receptors)1992Contraception, Dec, Volume: 46, Issue:6
Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (512)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.39)18.7374
1990's8 (1.56)18.2507
2000's214 (41.80)29.6817
2010's234 (45.70)24.3611
2020's54 (10.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 90.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index90.32 (24.57)
Research Supply Index6.56 (2.92)
Research Growth Index5.97 (4.65)
Search Engine Demand Index162.76 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (90.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials177 (33.40%)5.53%
Reviews90 (16.98%)6.00%
Case Studies25 (4.72%)4.05%
Observational7 (1.32%)0.25%
Other231 (43.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (71)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-center, Randomized, Open-label, Two-arm Study to Evaluate the Ovarian Function Inhibition of a Monophasic Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and a Monophasic COC Containing 20mcg Ethinyle [NCT03091595]Phase 282 participants (Actual)Interventional2017-02-07Completed
A Multicenter, Open-label, 3-arm, Active-controlled, Parallel-group, 1-year Study to Investigate the Efficacy and Safety of a Flexible Regimen of the Combined Oral Contraceptive, With and Without 0.451 mg Levomefolate Calcium (BAY98-7071 and BAY86-5300, R [NCT01331655]Phase 30 participants (Actual)Interventional2013-04-30Withdrawn
A Pilot, Randomized, Placebo-Controlled Trial Evaluating the Treatment of Premenstrual Dysphoric Disorder With Oral Contraceptives in Bipolar Disorder. [NCT05098574]Phase 260 participants (Anticipated)Interventional2022-11-30Recruiting
Drospirenone for Emergency Contraception: a Dose-finding Pilot Study [NCT05675644]Phase 235 participants (Anticipated)Interventional2023-02-28Not yet recruiting
A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone [NCT02817828]Phase 31,577 participants (Actual)Interventional2016-06-30Completed
The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of Polycystic Ovary Syndrome. [NCT03843736]Phase 3200 participants (Anticipated)Interventional2019-02-21Recruiting
Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS: an Open-label, Non-randomized Controlled Clinical Study [NCT05872425]120 participants (Anticipated)Interventional2023-02-01Recruiting
A Multicenter, Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of an Oral Contraceptive Preparation YAZ (Drospirenone 3 mg / Ethinylestradiol 20 µg) for 6 Treatment Cycles in Women With Moderate Acne [NCT00818519]Phase 3179 participants (Actual)Interventional2008-12-31Completed
Low Dose of Aspirin for the Management of Endometriosis-associated Pelvic Pain: a Randomized, Open, Controlled Trial [NCT05156879]Phase 4220 participants (Anticipated)Interventional2021-12-23Recruiting
A Multicenter, Open-Label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins [NCT01291004]Phase 1206 participants (Actual)Interventional2011-01-31Completed
A Phase 3, Multi-Center, Non-Comparative Study to Evaluate the Contraceptive Efficacy, Safety, and Tolerability of LPRI-CF113 Administered Orally for 13 Medication Cycles [NCT05461573]Phase 31,009 participants (Anticipated)Interventional2022-08-02Active, not recruiting
A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Fasting Conditions. [NCT01182194]Phase 132 participants (Actual)Interventional2006-06-30Completed
A Study in Healthy Female Participants to Investigate the Effect of JNJ-64530440 on the Single-dose of Ethinylestradiol and Drospirenone (Oral Contraceptive), and Midazolam, and the Effect of a High-fat Meal on the Single-dose of JNJ-64530440 [NCT03890341]Phase 10 participants (Actual)Interventional2021-06-01Withdrawn(stopped due to Stopped due to a strategic decision.)
Open-label, Randomized, Three-fold Crossover Study to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.02 mg Ethinylestradiol (EE) and 3 mg Drospirenone (DRSP) Without [SH T00186D] and With [SH T04532B] 0.451 mg L-mefolinat [NCT01253187]Phase 144 participants (Actual)Interventional2006-10-31Completed
A Double-blind, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Oral Estradiol / Drospirenone Regimens in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles [NCT00631124]Phase 2103 participants (Actual)Interventional2008-02-29Completed
The Effect of Oral Contraceptives on Dynamic Balance in Women [NCT02855294]Phase 4100 participants (Actual)Interventional2015-01-31Completed
A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of YAZ Compared With Placebo In The Treatment Of Hidradenitis Suppurativa [NCT00722800]Phase 24 participants (Actual)Interventional2008-10-31Terminated(stopped due to Poor recruitment)
A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone [NCT02817841]Phase 32,148 participants (Actual)Interventional2016-08-30Completed
A Multicenter, Open-label, Three-arm, Active-controlled Study to Assess the Efficacy and Safety of the Oral Contraceptive SH T00186D (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in Two Flexible Extended Regimens and a Conventiona [NCT00567164]Phase 31,887 participants (Actual)Interventional2007-10-31Completed
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Lowest Effective Dose of Combinations of Oral Drospirenone and 17 Beta-Estradiol for the Relief of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Over a Trea [NCT00446199]Phase 3735 participants (Actual)Interventional2007-03-31Completed
A Study to Characterize the Effect of Food on the Bioavailability of 15 mg Estetrol (E4)/3 mg Drospirenone (DRSP) Tablets in Healthy Female Volunteers [NCT02852681]Phase 128 participants (Actual)Interventional2015-08-31Completed
A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics Associated With the Use of a Combined Oral Contraceptive Containing 15 mg Estetrol Monohydrate and 3 mg Drospirenone in Post-menarchal Female Adolescents f [NCT04792385]Phase 3145 participants (Actual)Interventional2020-12-28Completed
A Multicenter, Open, Randomized, Parallel Group Comparison to Assess the Safety and Efficacy of the Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Betadex Clathrate and 3 mg Drospirenone) in Two Variations of an Extended Regimen vs. a Standard [NCT00266032]Phase 31,166 participants (Actual)Interventional2005-12-31Completed
A Multicenter, Single-blind, Randomized Study, to Investigate Efficacy of Ethinylestradiol for Intracyclic Bleeding Profile During 24 Weeks (6 Cycles) by Oral Administration of Drospirenone 3 mg/Ethinylestradiol 20 µg and Drospirenone 3 mg/ Ethinylestradi [NCT00461305]Phase 2/Phase 3420 participants (Actual)Interventional2007-02-28Completed
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq(drospirenon2mg and Estradiol 1mg) in Postmenopausal Korean Women With Vasomotor Symptoms Over 3, 28 Day Treatment Cycle [NCT00651599]Phase 390 participants (Actual)Interventional2004-07-31Completed
Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone [NCT00468481]Phase 3385 participants (Actual)Interventional2007-04-30Completed
Drospirenone and Ethinyl Estradiol Combinations (Yasmin) as Infertility Treatments for Premature Ovarian Failure: a Perspective Follow-up Study. [NCT02757469]20 participants (Anticipated)Interventional2016-05-31Not yet recruiting
Multi-center, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 16 μg LNG/Day Initial in Vitro Release Rate (LCS16) in Comparison t [NCT03074045]Phase 3145 participants (Actual)Interventional2017-03-13Completed
A Randomized, Double-blind, Placebo-controlled, Parallel, Single Center Study to Investigate the Pharmacokinetics, Safety, Tolerability, and QT Concentration-effect Modelling of Estetrol in Combination With Drospirenone After Single and Multiple Dosing in [NCT02874248]Phase 155 participants (Actual)Interventional2016-05-31Completed
Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives [NCT00640224]Phase 465 participants (Actual)Interventional2005-03-31Completed
A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy Of YAZ Compared With Placebo In The Treatment Of Moderate Truncal Acne Vulgaris [NCT00722761]Phase 330 participants (Actual)Interventional2009-04-30Completed
An Open Label Study to Evaluate Cycle Control With Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) and Yaz (Drospirenone/Ethinyl Estradiol) in Healthy Sexually Active Females [NCT00745901]Phase 4355 participants (Actual)Interventional2008-05-31Completed
A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehyperten [NCT00420342]Phase 292 participants (Actual)Interventional2007-01-31Completed
A Comparative Efficacy of Low-dose Combine Oral Contraceptives Containing Desogestrel 150 mg and Drospirenone 3 mg on Premenstrual Symptoms [NCT01482338]Phase 490 participants (Actual)Interventional2011-06-30Completed
The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants [NCT02027337]Phase 4200 participants (Anticipated)Interventional2013-12-31Recruiting
A Comparison of Body Weight Changing and Side Effects Between Treatment With 30 mcg Ethinylestradiol/2 mg Chlormadinone Acetate (Belara®) and 30 mcg Ethinylestradiol/3 mg Drospirenone (Yasmin®): A Randomized Control Trial [NCT01608698]Phase 4100 participants (Anticipated)Interventional2012-06-30Enrolling by invitation
Comparison of Oral Contraceptive Versus Physical Exercise Effects on Cardiovascular and Metabolic Risk Factors in PCOS Women [NCT00593294]Phase 4150 participants (Actual)Interventional2006-01-31Completed
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effects of Odalasvir and AL-335 at Steady-state, Given as Single Agents and in Combination With Simeprevir, on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone [NCT02885454]Phase 124 participants (Actual)Interventional2016-08-31Completed
A Multi-center, Double-blind, Randomized, Parallel-group Study to Evaluate Cycle Control and Safety of 6 Different Regimens of an Oral Contraceptive Containing Estradiol and Drospirenone in Healthy Female Volunteers Aged Between 18 and 35 Years Over 7 Cyc [NCT00653614]Phase 2635 participants (Actual)Interventional2008-03-31Completed
Effect of Combined Estradiol and Drospirenone Treatment Versus Combined Estradiol and Medroxyprogesterone Acetate Treatment on Endothelial Function: A Crossover Study [NCT01109979]Phase 424 participants (Actual)Interventional2009-12-31Completed
Open-label, Randomized, Three-fold Crossover Study to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.03 mg Ethinylestradiol (EE) and 3 mg Drospirenone (DRSP) Without [SH T470FA] and With [SH T04532A] 0.451 mg Metafolin®, [NCT01253174]Phase 148 participants (Actual)Interventional2006-08-31Completed
Polymorphisms in Genes Encoding the Estrogen Metabolism Enzymes and Effects of Hormone Therapy for Oral Low Dose or Not Oral on Variables Related Endothelial Function, Inflammation and Metabolic Profile in Patients in Recent Menopause Study Pharmacogeneti [NCT01432028]90 participants (Actual)Interventional2007-03-31Completed
A Randomized, Double-blind, Double-dummy, 2-parallel Arms Clinical Trial to Assess the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and to Compare the Profile of Circulating Folate Metabolites During 24 Weeks of Treatment With an Oral [NCT01258660]Phase 1172 participants (Actual)Interventional2006-12-31Completed
A Multicenter, Double-blind, Randomized, Placebo-controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17ß-estradiol 1 mg, Drospirenone 2 mg /17ß-estradiol 1 mg, Drospirenone 1 mg /17ß-estradiol 1 mg) Combinations and 17ß-estradiol (1 mg [NCT00102141]Phase 3750 participants (Actual)Interventional2004-04-30Completed
An Open-label, Non-randomized Study to Investigate the Effects of Twice-Daily Milvexian Administration on the Pharmacokinetics of Single Doses of Midazolam, Ethinylestradiol and Drospirenone in Healthy Adult Females [NCT05706753]Phase 120 participants (Actual)Interventional2023-01-25Completed
Research on Risk Factors and Comprehensive Intervention Measures of Polycystic Ovary Syndrome Complicated With Mental Diseases Such as Depression and Anxiety [NCT04984070]100 participants (Anticipated)Interventional2021-01-01Recruiting
A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Non-Fasting Conditions. [NCT01182207]Phase 133 participants (Actual)Interventional2006-07-31Completed
A Single Center, Randomized,Open-label,Controlled, Three-arm Study to Evaluate the Effect of a New Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and of Two Reference COCs Containing Either 30 mcg Ethinylestr [NCT02957630]Phase 1/Phase 2101 participants (Actual)Interventional2016-09-30Completed
[NCT01511822]Phase 40 participants InterventionalCompleted
Clinical Efficacy and Metabolic Impact of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Normal-weight Women With Polycystic Ovary Syndrome: a Randomized Study. [NCT01519401]50 participants (Actual)Interventional2010-02-28Completed
The Treatment of Menstrually-Related Mood Disorders With Extended Versus Interrupted Oral Contraceptives [NCT00089414]Phase 25 participants (Actual)Interventional2004-07-31Terminated(stopped due to Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of protocol.)
Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality [NCT01805817]Phase 40 participants (Actual)Interventional2012-12-31Withdrawn
The European Active Surveillance Study on OC Prescribing Practice, Benefits and Safety (EURAS) [NCT00302848]59,510 participants (Actual)Observational2000-11-30Completed
Metformin Plus EE30µg-drospirenone and Weight Loss- Impact on Endothelial Function and hsCRP Levels in PCOS [NCT01459445]26 participants (Anticipated)Interventional2011-02-28Active, not recruiting
A Multicenter, Open-label, Controlled Study to Investigate the Effect of Either LF111 or Drospirenone Chewable Tablets on Bone Mineral Density in Adolescent and Adult Women in Comparison With Non-users of Hormonal Contraceptive Methods [NCT05303636]Phase 41,710 participants (Anticipated)Interventional2022-03-28Recruiting
Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri [NCT03037944]Early Phase 132 participants (Anticipated)Interventional2016-03-01Recruiting
A Multicentre, Open, Uncontrolled Study to Assess Quality of Life During Six Cycles (24 Weeks) of Treatment With an Oral Contraceptive Containing 30 µg of Ethinylestradiol and 3 mg of Drospirenone (Yasmin). [NCT00367276]Phase 3221 participants (Actual)Interventional2002-12-31Completed
A Mechanistic Examination of Continuous Cycle Oral Contractive Administration in Binge Eating [NCT04278755]Phase 28 participants (Actual)Interventional2020-09-24Terminated(stopped due to Halted prematurely due to COVID-19-related enrollment challenges.)
The Oral Contraceptive Pill for Premenstrual Worsening of Depression. [NCT00633360]32 participants (Actual)Interventional2008-02-29Completed
Metabolic Syndrome in PCOS: Precursors and Interventions [NCT00442689]97 participants (Actual)Interventional2006-07-31Completed
Effects of Two Contraceptives Containing Drospirenone on Blood Pressure in Normotensive Women: a Randomized Controlled Trial [NCT02342093]Phase 444 participants (Actual)Interventional2011-01-31Completed
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midaz [NCT03111511]Phase 118 participants (Actual)Interventional2017-03-27Completed
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of Multiple Doses of BMS-986278 on the Pharmacokinetics of Combined Oral Contraceptives (Drospirenone/Ethinyl Estradiol) in Healthy Female Participants [NCT05985590]Phase 136 participants (Anticipated)Interventional2023-08-18Recruiting
A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants [NCT06039826]Phase 147 participants (Anticipated)Interventional2023-09-12Active, not recruiting
Evaluation of the Efficacy and Safety of Drospirenone in the Treatment of Adenomyosis [NCT06174792]40 participants (Anticipated)Observational2023-12-30Not yet recruiting
Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea? [NCT03124524]Phase 499 participants (Actual)Interventional2015-01-15Completed
Estetrol/Drospirenone to Reduce the Average Size of Endometriomas [NCT05837624]Phase 421 participants (Anticipated)Interventional2024-02-29Not yet recruiting
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Drug-drug Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone [NCT03126097]Phase 118 participants (Actual)Interventional2017-04-13Terminated(stopped due to Study stopping rules were met.)
Open-label, Randomized, Fixed Sequence Cross-over Study With Five Parallel Treatment Arms and Three Treatment Periods to Quantify the Drug-drug Interactions of Two Rifampicin Dose Strengths on Four Progestins and a Fixed Progestin-ethinylestradiol Combina [NCT03353857]Phase 168 participants (Actual)Interventional2017-11-29Completed
The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study [NCT05135013]200 participants (Anticipated)Observational2021-11-16Not yet recruiting
A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles [NCT02269241]Phase 31,552 participants (Actual)Interventional2014-10-09Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00266032 (12) [back to overview]Days With Scheduled Versus Unscheduled Bleeding
NCT00266032 (12) [back to overview]Adjusted Pearl Index
NCT00266032 (12) [back to overview]Pearl Index (FDA Criteria)
NCT00266032 (12) [back to overview]Number of Bleeding / Spotting Episodes in 90 Day Reference Period
NCT00266032 (12) [back to overview]Number of Bleeding / Spotting Days by 90-day Reference Period
NCT00266032 (12) [back to overview]Number of Unintended Pregnancies Including Pregnancies Occuring Within 14 Days After End of Study Medication.
NCT00266032 (12) [back to overview]Number of Unintended Pregnancies in Yaz Flexible Arm
NCT00266032 (12) [back to overview]Number of Unintended Pregnancies Due to Method Failure
NCT00266032 (12) [back to overview]Number of Days With Bleeding Including Spotting
NCT00266032 (12) [back to overview]Number of Days With Bleeding Excluding Spotting
NCT00266032 (12) [back to overview]Pearl Index
NCT00266032 (12) [back to overview]Number of Bleeding Days During One Year of Treatment in Subjects With at Least 248 Days of Exposure Normalized to 372 Days
NCT00302848 (1) [back to overview]Number of Participants With Venous Thromboembolism (VTE)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough
NCT00420342 (12) [back to overview]Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements
NCT00442689 (7) [back to overview]Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period
NCT00442689 (7) [back to overview]Change in Low-density Lipoprotein (LDL) Levels Over the Study Period
NCT00442689 (7) [back to overview]Change in High-density Lipoprotein (HDL) Levels During Study Period
NCT00442689 (7) [back to overview]Change in Disposition Index
NCT00442689 (7) [back to overview]Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI
NCT00442689 (7) [back to overview]Change in Resting Energy Expenditure (REE) Over the Study Period
NCT00442689 (7) [back to overview]Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period
NCT00446199 (18) [back to overview]Change From Baseline to Week 12 in Vaginal Maturation Value
NCT00446199 (18) [back to overview]Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)
NCT00446199 (18) [back to overview]Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'
NCT00446199 (18) [back to overview]Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'
NCT00446199 (18) [back to overview]Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'
NCT00446199 (18) [back to overview]Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'
NCT00446199 (18) [back to overview]Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)
NCT00446199 (18) [back to overview]Change From Baseline to Week 12 in Vaginal pH
NCT00446199 (18) [back to overview]Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)
NCT00446199 (18) [back to overview]Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)
NCT00446199 (18) [back to overview]Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)
NCT00446199 (18) [back to overview]Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)
NCT00446199 (18) [back to overview]Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)
NCT00446199 (18) [back to overview]Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'
NCT00446199 (18) [back to overview]Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'
NCT00446199 (18) [back to overview]Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'
NCT00446199 (18) [back to overview]Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'
NCT00446199 (18) [back to overview]Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)
NCT00461305 (37) [back to overview]Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6
NCT00461305 (37) [back to overview]Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6
NCT00461305 (37) [back to overview]Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6
NCT00461305 (37) [back to overview]Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13
NCT00461305 (37) [back to overview]Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 6
NCT00461305 (37) [back to overview]Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13
NCT00461305 (37) [back to overview]Number of Any Bleeding Days From Cycle 1 to Cycle 6
NCT00461305 (37) [back to overview]Number of Any Bleeding Days From Cycle 1 to Cycle 13
NCT00461305 (37) [back to overview]Distribution of Total Dysmenorrhea Score at Cycle 6
NCT00461305 (37) [back to overview]Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13
NCT00461305 (37) [back to overview]Distribution of Total Dysmenorrhea Score at Cycle 13
NCT00461305 (37) [back to overview]Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13
NCT00461305 (37) [back to overview]Change in Serum CRP From Baseline to Cycle 13
NCT00461305 (37) [back to overview]Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6
NCT00461305 (37) [back to overview]Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6
NCT00461305 (37) [back to overview]Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13
NCT00461305 (37) [back to overview]Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6
NCT00461305 (37) [back to overview]Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6
NCT00461305 (37) [back to overview]Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13
NCT00461305 (37) [back to overview]Number of Any Bleeding Episodes From Cycle 1 to Cycle 6
NCT00461305 (37) [back to overview]Number of Any Bleeding Episodes From Cycle 1 to Cycle 13
NCT00461305 (37) [back to overview]Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13
NCT00461305 (37) [back to overview]Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6
NCT00461305 (37) [back to overview]Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6
NCT00461305 (37) [back to overview]Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13
NCT00461305 (37) [back to overview]Distribution of Severity of Lumbago During Menstruation at Cycle 6
NCT00461305 (37) [back to overview]Change in Serum CA-125 From Baseline to Cycle 13
NCT00461305 (37) [back to overview]Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6
NCT00461305 (37) [back to overview]Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13
NCT00461305 (37) [back to overview]Distribution of Severity of Headache During Menstruation at Cycle 6
NCT00461305 (37) [back to overview]Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13
NCT00461305 (37) [back to overview]Distribution of Severity of Headache During Menstruation at Cycle 13
NCT00461305 (37) [back to overview]Change in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 6
NCT00461305 (37) [back to overview]Change in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 13
NCT00461305 (37) [back to overview]Number of Participants With Intracyclic Bleeding at Cycle 6
NCT00461305 (37) [back to overview]Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6
NCT00461305 (37) [back to overview]Distribution of Severity of Lumbago During Menstruation at Cycle 13
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline
NCT00468481 (47) [back to overview]Mean Neural Tube Defect (NTD) Risk Reduction at Week 24
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 8
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 4
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 24
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 20
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 16
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 12
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 8
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 4
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 20
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 16
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 12
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8
NCT00468481 (47) [back to overview]Plasma Folate Level at 24 Weeks
NCT00468481 (47) [back to overview]Red Blood Cell (RBC) Folate Level at 24 Weeks
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 4
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 3
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 2
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 14
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 13
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 11
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 10
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 1
NCT00567164 (24) [back to overview]Pearl Index
NCT00567164 (24) [back to overview]Number of Bleeding Days (Including Spotting Days)
NCT00567164 (24) [back to overview]Number of Bleeding Days (Excluding Spotting Days)
NCT00567164 (24) [back to overview]Length of Cycles
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 12
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 6
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 5
NCT00567164 (24) [back to overview]Number of Scheduled and Unscheduled Bleeding Days
NCT00567164 (24) [back to overview]Number of Intracyclic Bleeding Days
NCT00567164 (24) [back to overview]Number of Days With Bleeding/ (Including and Excluding Spotting) Within 90-day Reference Period 4
NCT00567164 (24) [back to overview]Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 3
NCT00567164 (24) [back to overview]Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 2.
NCT00567164 (24) [back to overview]Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 1.
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 9
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 8
NCT00567164 (24) [back to overview]Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 7
NCT00633360 (2) [back to overview]Percent Change in Daily Record of Severity of Problems (DRSP)
NCT00633360 (2) [back to overview]Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00640224 (23) [back to overview]Adiponectin at Baseline and 6 Months
NCT00640224 (23) [back to overview]Cholesterol at Baseline and 6 Months
NCT00640224 (23) [back to overview]Delta 17-OHProg at Baseline and 6 Months
NCT00640224 (23) [back to overview]Delta Androstenedione at Baseline and 6 Months
NCT00640224 (23) [back to overview]Delta DHEA at Baseline and 6 Months
NCT00640224 (23) [back to overview]DHEAS at Baseline and 6 Months
NCT00640224 (23) [back to overview]Free Testosterone at Baseline and 6 Months
NCT00640224 (23) [back to overview]Glucose Tolerance Status at Baseline and 6 Months.
NCT00640224 (23) [back to overview]HDL at Baseline and 6 Months
NCT00640224 (23) [back to overview]Hepatic Insulin Sensitivity at Baseline and 6 Months.
NCT00640224 (23) [back to overview]Hs-CRP at Baseline and 6 Months
NCT00640224 (23) [back to overview]LDL at Baseline and 6 Months
NCT00640224 (23) [back to overview]Leptin at Baseline and 6 Months
NCT00640224 (23) [back to overview]Morning Blood Pressure at Baseline and 6 Months
NCT00640224 (23) [back to overview]Non-HDL Cholesterol at Baseline and 6 Months
NCT00640224 (23) [back to overview]Percent Body Fat at Baseline and 6 Months
NCT00640224 (23) [back to overview]Peripheral Insulin Sensitivity at Baseline and 6 Months.
NCT00640224 (23) [back to overview]SHBG at Baseline and 6 Months
NCT00640224 (23) [back to overview]Total Fat Mass at Baseline and 6 Months
NCT00640224 (23) [back to overview]Night Blood Pressure at Baseline and 6 Months
NCT00640224 (23) [back to overview]Triglycerides at Baseline and 6 Months
NCT00640224 (23) [back to overview]Delta 17-OHPreg at Baseline and 6 Months
NCT00640224 (23) [back to overview]Total Testosterone at Baseline and 6 Months
NCT00722761 (2) [back to overview]Percent Change in Truncal Lesion Counts
NCT00722761 (2) [back to overview]Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination
NCT00722800 (3) [back to overview]Mean Improvement in the Sartorius Severity Score at Month 6.
NCT00722800 (3) [back to overview]Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Month 6.
NCT00722800 (3) [back to overview]Change From Baseline in VAS Pain Scale at Month 6.
NCT00745901 (20) [back to overview]Number of Days of Total Blood Loss - Cycle 1
NCT00745901 (20) [back to overview]Number of Days of Total Blood Loss - Cycle 2
NCT00745901 (20) [back to overview]Number of Days of Total Blood Loss - Cycle 3
NCT00745901 (20) [back to overview]Number of Days of Unscheduled Blood Loss - Cycle 1
NCT00745901 (20) [back to overview]Number of Days of Unscheduled Blood Loss - Cycle 2
NCT00745901 (20) [back to overview]Number of Days of Unscheduled Blood Loss - Cycle 3
NCT00745901 (20) [back to overview]Number of Participants With Breakthrough Bleeding/Spotting Cycle 1
NCT00745901 (20) [back to overview]Number of Participants With Breakthrough Bleeding/Spotting Cycle 2
NCT00745901 (20) [back to overview]Number of Participants With Breakthrough Bleeding/Spotting Cycle 3
NCT00745901 (20) [back to overview]Number of Participants With Unscheduled Bleeding Cycle 1
NCT00745901 (20) [back to overview]Number of Participants With Unscheduled Bleeding Cycle 2
NCT00745901 (20) [back to overview]Number of Participants With Unscheduled Bleeding Cycle 3
NCT00745901 (20) [back to overview]Overall Number of Days of Scheduled Blood Loss
NCT00745901 (20) [back to overview]Overall Number of Days of Total Blood Loss
NCT00745901 (20) [back to overview]Overall Number of Days of Unscheduled Blood Loss
NCT00745901 (20) [back to overview]Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes
NCT00745901 (20) [back to overview]Patient Satisfaction - Overall
NCT00745901 (20) [back to overview]Number of Days of Scheduled Blood Loss - Cycle 1
NCT00745901 (20) [back to overview]Number of Days of Scheduled Blood Loss - Cycle 2
NCT00745901 (20) [back to overview]Number of Days of Scheduled Blood Loss - Cycle 3
NCT00818519 (13) [back to overview]Percent Change From Cycle 6 to Baseline in Inflammatory Lesion Count (Papules, Pustules, and Nodules), Non-inflammatory Lesion Count
NCT00818519 (13) [back to overview]"Percentage of Participants Classified as Improved According to the Investigator's Overall Improvement Rating and on the Participant's Overall Self-Assessment Rating"
NCT00818519 (13) [back to overview]Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the PPS (Per Protocol Set)
NCT00818519 (13) [back to overview]Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the FAS (Full Analysis Set)
NCT00818519 (13) [back to overview]Percent Change From Cycle 6 to Baseline in Lesion Count of Pustules
NCT00818519 (13) [back to overview]Percent Change From Cycle 6 to Baseline in Lesion Count of Papules
NCT00818519 (13) [back to overview]Percent Change From Cycle 6 to Baseline in Lesion Count of Open Comedones
NCT00818519 (13) [back to overview]"Percentage of Participants Classified as 0 or 1 on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 1"
NCT00818519 (13) [back to overview]"Percentage of Participants Classified as 0 or 1 on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 3"
NCT00818519 (13) [back to overview]"Percentage of Participants Classified as 0 or 1 on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 6"
NCT00818519 (13) [back to overview]"Percentage of Participants Classified as 0 or 1 on the 6-point ISGA (Investigator Static Global Assessment) Scale at Screening Visit"
NCT00818519 (13) [back to overview]Percent Change From Cycle 6 to Baseline in Lesion Count of Closed Comedones
NCT00818519 (13) [back to overview]Percent Change From Cycle 6 to Baseline in Lesion Count of Nodules
NCT01109979 (1) [back to overview]Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD)
NCT01182194 (6) [back to overview]AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182194 (6) [back to overview]Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182194 (6) [back to overview]Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182194 (6) [back to overview]AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182194 (6) [back to overview]AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182194 (6) [back to overview]AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182207 (6) [back to overview]AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182207 (6) [back to overview]AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182207 (6) [back to overview]AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182207 (6) [back to overview]Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182207 (6) [back to overview]Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182207 (6) [back to overview]AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01253174 (12) [back to overview]Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation
NCT01253174 (12) [back to overview]Time to Reach Maximum Concentration (Tmax) of L-5-methyl-THF
NCT01253174 (12) [back to overview]Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation
NCT01253174 (12) [back to overview]Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation
NCT01253174 (12) [back to overview]Mean Maximum Concentration (Cmax) of DRSP Incl. Bioequivalence (BE) Evaluation
NCT01253174 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration up to 72h AUC(0-72h) of DRSP
NCT01253174 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation
NCT01253174 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation
NCT01253174 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of EE Incl. Bioequivalence (BE) Evaluation
NCT01253174 (12) [back to overview]Mean Area Under the Concentration-time Curve (AUC) of DRSP Incl. Bioequivalence (BE) Evaluation
NCT01253174 (12) [back to overview]Time to Reach Maximum Concentration (Tmax) of EE
NCT01253174 (12) [back to overview]Time to Reach Maximum Concentration (Tmax) of DRSP
NCT01253187 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of DRSP Incl. Bioequivalence (BE) Evaluation
NCT01253187 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of EE Incl. Bioequivalence (BE) Evaluation
NCT01253187 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation
NCT01253187 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation
NCT01253187 (12) [back to overview]Mean Maximum Concentration (Cmax) of DRSP Incl. Bioequivalence (BE) Evaluation
NCT01253187 (12) [back to overview]Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation
NCT01253187 (12) [back to overview]Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation
NCT01253187 (12) [back to overview]Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation
NCT01253187 (12) [back to overview]Time to Reach Maximum Concentration (Tmax) of DRSP
NCT01253187 (12) [back to overview]Time to Reach Maximum Concentration (Tmax) of EE
NCT01253187 (12) [back to overview]Time to Reach Maximum Concentration (Tmax) of L-5-methyl-THF
NCT01253187 (12) [back to overview]Mean Area Under the Concentration-time Curve From Administration up to 72h AUC(0-72h) of DRSP
NCT01258660 (8) [back to overview]Folate Metabolite Pattern in Plasma at Cycle 6
NCT01258660 (8) [back to overview]Homocysteine Concentrations in Plasma at Baseline and at the End of Treatment (Week 24) With Folic Acid
NCT01258660 (8) [back to overview]Homocysteine Concentrations in Plasma at Baseline and at the End of Treatment (Week 24) With Metafolin
NCT01258660 (8) [back to overview]Proportion of Participants With RBC Folate Below 906 Nmol/L in the Yasmin + Metafolin Group in the Folate Elimination Phase (Week 24 to 44)
NCT01258660 (8) [back to overview]Area Under the Curve (AUC) From Time 0 to 24 Weeks [AUC(0-24weeks)] for Plasma Folate and RBC (Red Blood Cell) Folate (Baseline Uncorrected)
NCT01258660 (8) [back to overview]Area Under the Curve From Time 0 to 24 Weeks [AUC(0-24weeks)] for Plasma Folate and RBC (Red Blood Cell) Folate (Baseline Corrected)
NCT01258660 (8) [back to overview]Folate Metabolite Pattern in Plasma at Baseline
NCT01258660 (8) [back to overview]Folate Metabolite Pattern in Plasma at Cycle 3
NCT02269241 (9) [back to overview]Number of Pregnancies (Evaluable Cycles)
NCT02269241 (9) [back to overview]Tolerability; Vaginal Bleeding Pattern
NCT02269241 (9) [back to overview]Pregnancy Ratio
NCT02269241 (9) [back to overview]Overall PI, PI for Method Failures
NCT02269241 (9) [back to overview]Number of Pregnancies (Method Failures)
NCT02269241 (9) [back to overview]Overall Pregnancies
NCT02269241 (9) [back to overview]Number of Participants With Adverse Events as a Measure of Safety
NCT02269241 (9) [back to overview]Number of Pregnancies (All)
NCT02269241 (9) [back to overview]Number of Pregnancies (by BMI and Weight)
NCT02817828 (17) [back to overview]Number of Subjects With Abnormal Physical Examination Results
NCT02817828 (17) [back to overview]Number of Subjects With Abnormal Gynecological Examination Results
NCT02817828 (17) [back to overview]Endometrial Biopsy Histology at Screening and End of Treatment
NCT02817828 (17) [back to overview]Number of Unscheduled Spotting Days Per Cycle
NCT02817828 (17) [back to overview]Number of Unscheduled Bleeding Days Per Cycle
NCT02817828 (17) [back to overview]Number of Subjects With Unscheduled Bleeding/Spotting
NCT02817828 (17) [back to overview]Number of Subjects With Absence of Scheduled Bleeding and/or Spotting
NCT02817828 (17) [back to overview]Number of Scheduled Bleeding and/or Spotting Days Per Cycle
NCT02817828 (17) [back to overview]Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)
NCT02817828 (17) [back to overview]The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years)
NCT02817828 (17) [back to overview]The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years)
NCT02817828 (17) [back to overview]The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening
NCT02817828 (17) [back to overview]Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)
NCT02817828 (17) [back to overview]Number of Subjects With Abnormal Vital Signs
NCT02817828 (17) [back to overview]Number of Subjects With Abnormal Laboratory Assessment Results
NCT02817828 (17) [back to overview]The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening
NCT02817828 (17) [back to overview]Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction Over the Past Week
NCT02817841 (22) [back to overview]Number of Unscheduled Spotting Days Per Cycle
NCT02817841 (22) [back to overview]Number of Unscheduled Bleeding Days Per Cycle
NCT02817841 (22) [back to overview]Number of Subjects With Unscheduled Bleeding/Spotting Episodes
NCT02817841 (22) [back to overview]Number of Subjects With Bleeding and/or Spotting Episodes by Reference Period
NCT02817841 (22) [back to overview]Number of Subjects With Absence of Scheduled Bleeding and/or Spotting
NCT02817841 (22) [back to overview]Number of Participants With Clinically Abnormal Gynecological Examination Results
NCT02817841 (22) [back to overview]Mean Number of Bleeding and Spotting Days by Reference Period
NCT02817841 (22) [back to overview]Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)
NCT02817841 (22) [back to overview]The Number of On-treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (16-50 Years)
NCT02817841 (22) [back to overview]The Number of On-treatment Pregnancies (With +7-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 16 to 35 Years, Inclusive, at the Time of Screening
NCT02817841 (22) [back to overview]The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (16-50 Years)
NCT02817841 (22) [back to overview]The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 16 to 35 Years, Inclusive, at the Time of Screening
NCT02817841 (22) [back to overview]Rate of Pregnancy (Life-table Analysis) in Participants Aged 16 to 50 Years
NCT02817841 (22) [back to overview]Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction and Contentment Over the Past Week
NCT02817841 (22) [back to overview]Number of Participants With Clinically Abnormal Physical Examination Results
NCT02817841 (22) [back to overview]Rate of Pregnancy (Life-table Analysis) in Participants Aged 16 to 35 Years
NCT02817841 (22) [back to overview]Number of Participants With Clinically Significant out-of Range Hematology Results
NCT02817841 (22) [back to overview]Number of Participants With Clinically Significant out-of Range Serum Chemistry and Lipid Profile Results
NCT02817841 (22) [back to overview]Number of Subjects With Clinically Abnormal Vital Signs
NCT02817841 (22) [back to overview]Number of Subjects With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability.
NCT02817841 (22) [back to overview]Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)
NCT02817841 (22) [back to overview]Number of Scheduled Bleeding and/or Spotting Days Per Cycle
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Behavioral Inhibition Subscale Score
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Binge Eating Sum Score
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Delay Discounting Parameter k
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Nucleus Accumbens Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Prefrontal Cortex Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Self-reported Reward Sensitivity Subscale Score
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Weekly Average Binge-eating Frequency
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Dorsal Striatum Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

Days With Scheduled Versus Unscheduled Bleeding

Days with scheduled and unscheduled bleeding were evaluated for extended regimens only. Unscheduled is any bleeding/spotting that occurred while taking active hormones regardless of the duration of intake, unless they occurred after tablet-free interval during days 1-4 of subsequent treatment cycle, or unless they occurred during days 1-7 of first treatment cycle. Scheduled is any bleeding/spotting that occurred during tablet-free interval, regardless of duration of tablet intake, or during next 4 days of subsequent treatment cycle. (NCT00266032)
Timeframe: Up to one year

,
InterventionDays (Mean)
Scheduled bleedingUnscheduled bleeding
Fixed Extended Treatment of EE20/DRSP (YAZ, BAY86-5300)14.046.6
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)23.317.1

[back to top]

Adjusted Pearl Index

The adjusted Pearl Index was based on pregnancies due to method failures and compliant treatment cycles, i.e. cycle length between 24 and 124 day, pill break not longer than 7 days, and number of pills taken not smaller than 90% of the number of days in that cycle minus 7 days. (NCT00266032)
Timeframe: Up to 2 years

InterventionPregnancies per 100 woman years (Mean)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)0.60

[back to top]

Pearl Index (FDA Criteria)

Following an FDA request another PI evaluation was done for the first year of treatment only and taking into consideration also pregnancies with a conception date within 14 days after end of the study medication. Restricting the analysis to the required first year of treatment, it results in this PI estimation. (NCT00266032)
Timeframe: Up to one year

InterventionPregnancies per 100 woman years (Mean)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)0.34

[back to top]

Number of Bleeding / Spotting Episodes in 90 Day Reference Period

The mean number of bleeding / spotting episodes was analyzed using reference periods of 90 days as recommended by the WHO. (NCT00266032)
Timeframe: Up to one year

,,
InterventionEpisodes (Mean)
Reference period 1Reference period 2Reference period 3Reference period 4
Fixed Extended Treatment of EE20/DRSP (YAZ, BAY86-5300)2.02.12.11.3
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)1.71.91.71.5
Standard 24+4 Treatment of EE20/DRSP (YAZ, BAY86-5300)3.43.43.23.2

[back to top]

Number of Bleeding / Spotting Days by 90-day Reference Period

The mean number of bleeding / spotting days, spotting-only and bleeding days was analyzed using reference periods of 90 days as recommended by the WHO. (NCT00266032)
Timeframe: up to 1 year

,,
InterventionDays (Mean)
Reference period 1Reference period 2Reference period 3Reference period 4
Fixed Extended Treatment of EE20/DRSP (YAZ, BAY86-5300)9.06.35.12.6
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)7.25.34.63.9
Standard 24+4 Treatment of EE20/DRSP (YAZ, BAY86-5300)14.610.29.89.5

[back to top]

Number of Unintended Pregnancies Including Pregnancies Occuring Within 14 Days After End of Study Medication.

Pregnancies with conception date during treatment and within 14 days after end of study medication were included. (NCT00266032)
Timeframe: Up to one year

InterventionPregnancies (Number)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)2

[back to top]

Number of Unintended Pregnancies in Yaz Flexible Arm

Pregnancies with conception date within 4 days after end of study medication were regarded as during treatment. (NCT00266032)
Timeframe: up to 2 years

Interventionpregnancies (Number)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)8

[back to top]

Number of Unintended Pregnancies Due to Method Failure

Not included in this analysis are pregnancies due to subject failure eg. non-compliance with tablet intake rules. (NCT00266032)
Timeframe: Up to 2 years

InterventionPregnancies (Number)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)7

[back to top]

Number of Days With Bleeding Including Spotting

The number of bleeding days per volunteer was calculated by summing up all days with bleeding intensity spotting or worse. The primary evaluation was the comparison of the flexible extended vs the standard regimen for this primary target variable, which was done for data within the first year of treatment only. As no further comparison or testing was done, no multiplicity issue arose. (NCT00266032)
Timeframe: up to 1 year

Interventiondays (Mean)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)41
Fixed Extended Treatment of EE20/DRSP (YAZ, BAY86-5300)61
Standard 24+4 Treatment of EE20/DRSP (YAZ, BAY86-5300)66

[back to top]

Number of Days With Bleeding Excluding Spotting

The number of bleeding days per volunteer was calculated by summing up all days with bleeding intensity light, normal, or heavy. (NCT00266032)
Timeframe: up to 1 year

InterventionDays (Mean)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)21
Fixed Extended Treatment of EE20/DRSP (YAZ, BAY86-5300)24
Standard 24+4 Treatment of EE20/DRSP (YAZ, BAY86-5300)43

[back to top]

Pearl Index

The Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 2-year PI was obtained by dividing the number of pregnancies that occurred during the two years of treatment by the time (in 100 women years) that the women were under risk of getting pregnant. 95% confidence interval according to European Medicine Agency Note for guidance on clinical investigation of steroid contraceptives in women. (NCT00266032)
Timeframe: Up to 2 years

InterventionPregnancies per 100 woman years (Mean)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)0.64

[back to top]

Number of Bleeding Days During One Year of Treatment in Subjects With at Least 248 Days of Exposure Normalized to 372 Days

For early dropouts and pregnant subjects with an exposure period of less than 1 year but at least 248 days, the number of bleeding/spotting days was normalized to correspond to a 1-year exposure period. (NCT00266032)
Timeframe: up to 1 year

InterventionDays (Mean)
Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)44
Fixed Extended Treatment of EE20/DRSP (YAZ, BAY86-5300)66
Standard 24+4 Treatment of EE20/DRSP (YAZ, BAY86-5300)71

[back to top]

Number of Participants With Venous Thromboembolism (VTE)

(NCT00302848)
Timeframe: 1.5 to 5 years

InterventionParticipants (Number)
Users of DRSP26
Users of LNG25

[back to top]

Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements

Diastolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle) (NCT00420342)
Timeframe: Baseline to Week 8

,,
InterventionmmHg (Median)
mean daytimemean nighttimemean trough
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.950.20-1.04
1.5 mg MPA / 0.3 mg CEE (Prempro)0.171.75-0.30
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.560.67-1.13

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-5.2
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-4.0
1.5 mg MPA / 0.3 mg CEE (Prempro)1.0

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-3.4
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-4.4
1.5 mg MPA / 0.3 mg CEE (Prempro)1.1

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-2.6
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-3.7
1.5 mg MPA / 0.3 mg CEE (Prempro)1.1

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-2.4
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-2.2
1.5 mg MPA / 0.3 mg CEE (Prempro)2.0

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.9
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.9
1.5 mg MPA / 0.3 mg CEE (Prempro)1.4

[back to top]

Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population

The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the full analysis set. The change from baseline means was adjusted for center and baseline SBP. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.03
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-0.27
1.5 mg MPA / 0.3 mg CEE (Prempro)2.18

[back to top]

Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population

The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the per protocol (PP) population. The change from baseline means was adjusted for center and baseline SBP. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.08
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)0.06
1.5 mg MPA / 0.3 mg CEE (Prempro)2.82

[back to top]

Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements

The mean change in 24-hr Diastolic Blood Pressure (DBP) from Baseline to Week 8 was calculated for the full analysis set. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.19
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-0.91
1.5 mg MPA / 0.3 mg CEE (Prempro)0.57

[back to top]

Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough

Seated systolic and diastolic office cuff blood pressures were taken at each visit; the mean of three readings were used at each timepoint. (NCT00420342)
Timeframe: Baseline to Week 8

,,
InterventionmmHg (Mean)
Systolic Blood Pressure (SBP)Diastolic Blood Pressure (DBP)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-5.25-1.34
1.5 mg MPA / 0.3 mg CEE (Prempro)-4.200.33
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-6.02-0.36

[back to top]

Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8

Sodium sensitivity was defined as ≥ 10 mmHg drop in mean arterial pressure, calculated from the office cuff BP values from Day 1 to Day 3. The number of subjects shifting from sodium sensitive at Baseline to sodium resistant at Week 8 or sodium resistant at Baseline to sodium sensitive at Week 8 by treatment group was reported. (NCT00420342)
Timeframe: 8 weeks plus 3 days

,,
Interventionparticipants (Number)
BaselineWeek 8
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)41
1.5 mg MPA / 0.3 mg CEE (Prempro)42
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)32

[back to top]

Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements

Systolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle) (NCT00420342)
Timeframe: Baseline to Week 8

,,
InterventionmmHg (Mean)
mean daytimemean nighttimemean trough
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-2.081.57-1.91
1.5 mg MPA / 0.3 mg CEE (Prempro)1.533.97-1.51
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.061.64-1.48

[back to top]

Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period

Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months

InterventionL/min (Mean)
Oral Contraceptive - 1-0.5
Flutamide - 2-1.6
Placebo - 31.1

[back to top]

Change in Low-density Lipoprotein (LDL) Levels Over the Study Period

Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months

Interventionmg/dL (Mean)
Oral Contraceptive - 1-6
Flutamide - 2-9
Placebo - 3-7

[back to top]

Change in High-density Lipoprotein (HDL) Levels During Study Period

Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months

Interventionmg/dL (Mean)
Oral Contraceptive - 16
Flutamide - 2-5
Placebo - 3-2

[back to top]

Change in Disposition Index

Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months

Interventionmin^-1 (Mean)
Oral Contraceptive - 11653
Flutamide - 2194
Placebo - 3-184

[back to top]

Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI

Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months

InterventionL (Mean)
Oral Contraceptive - 1-0.1
Flutamide - 2-0.1
Placebo - 30.1

[back to top]

Change in Resting Energy Expenditure (REE) Over the Study Period

Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months

InterventionKcal/day (Mean)
Oral Contraceptive - 17
Flutamide - 2-79
Placebo - 3-88

[back to top]

Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period

Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months

Interventionpercentage of body mass (Mean)
Oral Contraceptive - 10.4
Flutamide - 2-1.9
Placebo - 3-1.9

[back to top]

Change From Baseline to Week 12 in Vaginal Maturation Value

Calculated as (percentage of superficial cells) + 0.5 * (percentage of intermediate cells). Absolute change calculated as week 12 value minus baseline value. (NCT00446199)
Timeframe: Baseline until 12 weeks of treatment

InterventionPercentages of cells (Mean)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)10.07
0.25mg DRSP / 0.5mg E2 (BAY86-4891)11.71
Estradiol (E2 0.3mg)7.69
Placebo-2.41

[back to top]

Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity of moderate to severe hot flushes minus baseline severity. (NCT00446199)
Timeframe: Baseline until 4 weeks of treatment

InterventionScorese on a scale (Median)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-0.2905
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-0.1821
Estradiol (E2 0.3mg)-0.0651
Placebo0.0000

[back to top]

Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'

Subjects self-assessed presence or absence of symptom (NCT00446199)
Timeframe: After 12 weeks of treatment

Interventionparticipants (Number)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)45
0.25mg DRSP / 0.5mg E2 (BAY86-4891)56
Estradiol (E2 0.3mg)62
Placebo57

[back to top]

Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'

Subjects self-assessed presence or absence of symptom (NCT00446199)
Timeframe: After 12 weeks of treatment

Interventionparticipants (Number)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)70
0.25mg DRSP / 0.5mg E2 (BAY86-4891)53
Estradiol (E2 0.3mg)53
Placebo48

[back to top]

Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'

Subjects self-assessed presence or absence of symptom; and if present recorded average number of times per night: 1; 2 to 4; more than 4. (NCT00446199)
Timeframe: After 12 weeks of treatment

Interventionparticipants (Number)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)99
0.25mg DRSP / 0.5mg E2 (BAY86-4891)114
Estradiol (E2 0.3mg)114
Placebo111

[back to top]

Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'

Subjects self-assessed symptom severity (NCT00446199)
Timeframe: After 12 weeks of treatment

,,,
Interventionparticipants (Number)
nonemildmoderatesevere
0.25mg DRSP / 0.5mg E2 (BAY86-4891)169200
0.5mg DRSP / 0.5mg E2 (BAY86-4891)166600
Estradiol (E2 0.3mg)167111
Placebo153900

[back to top]

Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number. (NCT00446199)
Timeframe: Baseline until 4 weeks of treatment

InterventionHot Flushes per week (Mean)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-48.810
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-38.989
Estradiol (E2 0.3mg)-32.633
Placebo-24.195

[back to top]

Change From Baseline to Week 12 in Vaginal pH

Vaginal pH determined following speculum examination using vaginal pH paper and recorded on case report form (CRF). Absolute change calculated as week 12 pH minus baseline pH. (NCT00446199)
Timeframe: Baseline until 12 weeks of treatment

Intervention(pH) (Mean)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-0.63
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-0.63
Estradiol (E2 0.3mg)-0.66
Placebo-0.06

[back to top]

Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number. (NCT00446199)
Timeframe: Baseline until 12 weeks of treatment

InterventionHot Flushes per week (Mean)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-60.331
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-55.317
Estradiol (E2 0.3mg)-41.783
Placebo-31.916

[back to top]

Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number. (NCT00446199)
Timeframe: Baseline until 12 weeks of treatment

InterventionHot Flushes per week (Median)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-54.515
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-54.125
Estradiol (E2 0.3mg)-44.389
Placebo-30.020

[back to top]

Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity moderate to severe hot flushes minus baseline severity. (NCT00446199)
Timeframe: Baseline until 12 weeks of treatment

InterventionScores on a scale (Mean)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-1.4473
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-1.2141
Estradiol (E2 0.3mg)-0.7822
Placebo-0.3873

[back to top]

Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity of moderate to severe hot flushes minus baseline severity. (NCT00446199)
Timeframe: Baseline until 12 weeks of treatment

InterventionScores on a scale (Median)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-1.9294
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-1.000
Estradiol (E2 0.3mg)-0.2638
Placebo-0.0698

[back to top]

Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number. (NCT00446199)
Timeframe: Baseline until 4 weeks of treatment

InterventionHot Flushes per week (Median)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-46.868
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-37.596
Estradiol (E2 0.3mg)-31.621
Placebo-15.109

[back to top]

Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'

Subjects self-assessed symptom severity (NCT00446199)
Timeframe: After 12 weeks of treatment

,,,
Interventionparticipants (Number)
nonemildmoderatesevere
0.25mg DRSP / 0.5mg E2 (BAY86-4891)1402434
0.5mg DRSP / 0.5mg E2 (BAY86-4891)1522000
Estradiol (E2 0.3mg)1462150
Placebo12822113

[back to top]

Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'

Subjects self-assessed symptom severity (NCT00446199)
Timeframe: After 12 weeks of treatment

,,,
Interventionparticipants (Number)
nonemildmoderatesevere
0.25mg DRSP / 0.5mg E2 (BAY86-4891)162210
0.5mg DRSP / 0.5mg E2 (BAY86-4891)164200
Estradiol (E2 0.3mg)159300
Placebo151200

[back to top]

Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'

Subjects self-assessed symptom severity (NCT00446199)
Timeframe: After 12 weeks of treatment

,,,
Interventionparticipants (Number)
nonemildmoderatesevere
0.25mg DRSP / 0.5mg E2 (BAY86-4891)70523811
0.5mg DRSP / 0.5mg E2 (BAY86-4891)8359246
Estradiol (E2 0.3mg)71622910
Placebo70473512

[back to top]

Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'

Subjects self-assessed symptom severity (NCT00446199)
Timeframe: After 12 weeks of treatment

,,,
Interventionparticipants (Number)
nonemildmoderatesevere
0.25mg DRSP / 0.5mg E2 (BAY86-4891)1322274
0.5mg DRSP / 0.5mg E2 (BAY86-4891)12821134
Estradiol (E2 0.3mg)12721113
Placebo11819114

[back to top]

Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)

Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity moderate to severe hot flushes minus baseline severity. (NCT00446199)
Timeframe: Baseline until 4 weeks of treatment

Interventionscores on a scale (Mean)
0.5mg DRSP / 0.5mg E2 (BAY86-4891)-0.8347
0.25mg DRSP / 0.5mg E2 (BAY86-4891)-0.5859
Estradiol (E2 0.3mg)-0.4033
Placebo-0.1926

[back to top]

Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6

CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation. (NCT00461305)
Timeframe: From baseline up to Cycle 6 (168 days) with 28 days per cycle

Interventionmg/dL (Mean)
DRSP 3 mg/EE 20 µg (6 Cycles)0.159
DRSP 3 mg/EE 30 µg (6 Cycles)0.000

[back to top]

Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6

VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced). (NCT00461305)
Timeframe: From baseline up to Cycle 6 (168 days) with 28 days per cycle

Interventionscores on a scale (Mean)
DRSP 3 mg/EE 20 µg (6 Cycles)-37.2
DRSP 3 mg/EE 30 µg (6 Cycles)-31.9

[back to top]

Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6

Intracyclic bleedings were defined as bleedings while a participant takes active tablets. (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6
DRSP 3 mg/EE 20 µg (6 Cycles)943845334029
DRSP 3 mg/EE 30 µg (6 Cycles)1988354

[back to top]

Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13

Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets. (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12Cycle 13
DRSP 3 mg/EE 20 µg (13 Cycles)274314307295289285229259245250246243241

[back to top]

Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 6

Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets. (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6
DRSP 3 mg/EE 20 µg (6 Cycles)276310302290279185
DRSP 3 mg/EE 30 µg (6 Cycles)545758545452

[back to top]

Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13

Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding). (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

InterventionPercentage of participants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12Cycle 13
DRSP 3 mg/EE 20 µg (13 Cycles)90.397.491.187.987.892.590.4100.087.5100.0100.0100.090.3

[back to top]

Number of Any Bleeding Days From Cycle 1 to Cycle 6

Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days). (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventiondays (Mean)
Reference period 1Reference period 2
DRSP 3 mg/EE 20 µg (6 Cycles)30.719.3
DRSP 3 mg/EE 30 µg (6 Cycles)28.919.9

[back to top]

Number of Any Bleeding Days From Cycle 1 to Cycle 13

Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 4 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days). (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventiondays (Mean)
Reference period 1Reference period 2Reference period 3Reference period 4
DRSP 3 mg/EE 20 µg (13 Cycles)30.619.821.217.7

[back to top]

Distribution of Total Dysmenorrhea Score at Cycle 6

Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest. (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
0123456
DRSP 3 mg/EE 20 µg (6 Cycles)6579494219171
DRSP 3 mg/EE 30 µg (6 Cycles)131698341

[back to top]

Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13

Intracyclic bleedings were defined as bleedings while a participant takes active tablets. (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12Cycle 13
DRSP 3 mg/EE 20 µg (13 Cycles)933845334140114242424212331

[back to top]

Distribution of Total Dysmenorrhea Score at Cycle 13

Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest. (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
0123456
DRSP 3 mg/EE 20 µg (13 Cycles)7366412424131

[back to top]

Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13

VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced). (NCT00461305)
Timeframe: From baseline up to Cycle 13 (364 days) with 28 days per cycle

Interventionscores on a scale (Mean)
DRSP 3 mg/EE 20 µg (13 Cycles)-41.6

[back to top]

Change in Serum CRP From Baseline to Cycle 13

CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation. (NCT00461305)
Timeframe: From baseline up to Cycle 13 (364 days) with 28 days per cycle

Interventionmg/dL (Mean)
DRSP 3 mg/EE 20 µg (13 Cycles)0.014

[back to top]

Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6

CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor. (NCT00461305)
Timeframe: From baseline up to Cycle 6 (168 days) with 28 days per cycle

InterventionUnits/mL (Mean)
DRSP 3 mg/EE 20 µg (6 Cycles)-4.33
DRSP 3 mg/EE 30 µg (6 Cycles)-5.50

[back to top]

Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6

Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest. (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
0123456
DRSP 3 mg/EE 20 µg (6 Cycles)20252112220
DRSP 3 mg/EE 30 µg (6 Cycles)341341101

[back to top]

Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13

Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest. (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
0123456
DRSP 3 mg/EE 20 µg (13 Cycles)17749122200

[back to top]

Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6

Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding). (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
InterventionPercentage of participants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6
DRSP 3 mg/EE 20 µg (6 Cycles)90.397.491.187.987.892.5
DRSP 3 mg/EE 30 µg (6 Cycles)89.5100.0100.0100.080.0100.0

[back to top]

Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6

Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change. (NCT00461305)
Timeframe: From baseline up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
-6 (change in total dysmenorrhea scores)-5 (change in total dysmenorrhea scores)-4 (change in total dysmenorrhea scores)-3 (change in total dysmenorrhea scores)-2 (change in total dysmenorrhea scores)-1 (change in total dysmenorrhea scores)0 (change in total dysmenorrhea scores)1 (change in total dysmenorrhea scores)2 (change in total dysmenorrhea scores)3 (change in total dysmenorrhea scores)4 (change in total dysmenorrhea scores)5 (change in total dysmenorrhea scores)6 (change in total dysmenorrhea scores)
DRSP 3 mg/EE 20 µg (6 Cycles)5224170713025440000
DRSP 3 mg/EE 30 µg (6 Cycles)2381310124200000

[back to top]

Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13

Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change. (NCT00461305)
Timeframe: From baseline up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
-6 (change in total dysmenorrhea scores)-5 (change in total dysmenorrhea scores)-4 (change in total dysmenorrhea scores)-3 (change in total dysmenorrhea scores)-2 (change in total dysmenorrhea scores)-1 (change in total dysmenorrhea scores)0 (change in total dysmenorrhea scores)1 (change in total dysmenorrhea scores)2 (change in total dysmenorrhea scores)3 (change in total dysmenorrhea scores)4 (change in total dysmenorrhea scores)5 (change in total dysmenorrhea scores)6 (change in total dysmenorrhea scores)
DRSP 3 mg/EE 20 µg (13 Cycles)42247684432121120000

[back to top]

Number of Any Bleeding Episodes From Cycle 1 to Cycle 6

Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days). (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionnumber of episodes (Mean)
Reference period 1Reference period 2
DRSP 3 mg/EE 20 µg (6 Cycles)3.33.3
DRSP 3 mg/EE 30 µg (6 Cycles)3.43.1

[back to top]

Number of Any Bleeding Episodes From Cycle 1 to Cycle 13

Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days). (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionnumber of episodes (Mean)
Reference period 1Reference period 2Reference period 3Reference period 4
DRSP 3 mg/EE 20 µg (13 Cycles)3.23.53.13.2

[back to top]

Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13

VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced). (NCT00461305)
Timeframe: From baseline up to Cycle 13 (364 days) with 28 days per cycle

Interventionscores on a scale (Mean)
DRSP 3 mg/EE 20 µg (13 Cycles)6.2

[back to top]

Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6

Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding). (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
InterventionPercentage of participants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6
DRSP 3 mg/EE 20 µg (6 Cycles)90.190.891.292.292.790.9
DRSP 3 mg/EE 30 µg (6 Cycles)87.094.787.992.688.988.5

[back to top]

Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6

Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities). (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
nonemildmoderatesevere
DRSP 3 mg/EE 20 µg (6 Cycles)2511443
DRSP 3 mg/EE 30 µg (6 Cycles)51120

[back to top]

Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13

Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities). (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
nonemildmoderatesevere
DRSP 3 mg/EE 20 µg (13 Cycles)2291120

[back to top]

Distribution of Severity of Lumbago During Menstruation at Cycle 6

Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities). (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
nonemildmoderatesevere
DRSP 3 mg/EE 20 µg (6 Cycles)15488264
DRSP 3 mg/EE 30 µg (6 Cycles)212922

[back to top]

Change in Serum CA-125 From Baseline to Cycle 13

CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor. (NCT00461305)
Timeframe: From baseline up to Cycle 13 (364 days) with 28 days per cycle

InterventionUnits/mL (Mean)
DRSP 3 mg/EE 20 µg (13 Cycles)-4.66

[back to top]

Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6

Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities). (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
nonemildmoderatesevere
DRSP 3 mg/EE 20 µg (6 Cycles)751195919
DRSP 3 mg/EE 30 µg (6 Cycles)1419165

[back to top]

Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13

Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities). (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
nonemildmoderatesevere
DRSP 3 mg/EE 20 µg (13 Cycles)781064711

[back to top]

Distribution of Severity of Headache During Menstruation at Cycle 6

Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities). (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionparticipants (Number)
nonemildmoderatesevere
DRSP 3 mg/EE 20 µg (6 Cycles)187412915
DRSP 3 mg/EE 30 µg (6 Cycles)374112

[back to top]

Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13

Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding). (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

InterventionPercentage of participants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12Cycle 13
DRSP 3 mg/EE 20 µg (13 Cycles)90.190.891.292.292.790.991.391.191.090.891.993.893.8

[back to top]

Distribution of Severity of Headache During Menstruation at Cycle 13

Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities). (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
nonemildmoderatesevere
DRSP 3 mg/EE 20 µg (13 Cycles)16838306

[back to top]

Change in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 6

Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest. (NCT00461305)
Timeframe: Baseline and up to Cycle 6 (168 days) with 28 days per cycle

,
Interventionscores on a scale (Mean)
age: < 30 yearsage: >= 30 yearsweight: < 50 kgweight: >= 50kgfunctional dysmenorrheaorganic dysmenorrheawith medical surgical historywithout medical surgical historywith previous medicationwith pregnancy historywith birth historytotal dysmenorrhea score at baseline 3/4total dysmenorrhea score at baseline 5/6
DRSP 3 mg/EE 20 µg (6 Cycles)-2.4-2.2-2.0-2.5-2.4-2.0-2.3-2.4-2.3-2.2-2.0-1.9-3.0
DRSP 3 mg/EE 30 µg (6 Cycles)-2.2-2.1-2.3-2.0-2.3-1.3-2.0-2.4-2.1-2.1-2.4-1.9-2.6

[back to top]

Change in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 13

Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest. (NCT00461305)
Timeframe: Baseline and up to Cycle 13 (364 days) with 28 days per cycle

Interventionscores on a scale (Mean)
age: < 30 yearsage: >= 30 yearsweight: < 50 kgweight: >= 50kgfunctional dysmenorrheaorganic dysmenorrheawith medical surgical historywithout medical surgical historywith previous medicationwith pregnancy historywith birth historytotal dysmenorrhea score at baseline 3/4total dysmenorrhea score at baseline 5/6
DRSP 3 mg/EE 20 µg (13 Cycles)-2.5-2.4-2.1-2.7-2.6-2.1-2.5-2.5-2.5-2.1-1.9-2.0-3.2

[back to top]

Number of Participants With Intracyclic Bleeding at Cycle 6

Intracyclic bleedings were defined as bleedings while a participant takes active tablets. (NCT00461305)
Timeframe: Up to Cycle 6 (168 days) with 28 days per cycle

Interventionparticipants (Number)
DRSP 3 mg/EE 20 µg (6 Cycles)40
DRSP 3 mg/EE 30 µg (6 Cycles)4

[back to top]

Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6

VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced). (NCT00461305)
Timeframe: From baseline up to Cycle 6 (168 days) with 28 days per cycle

Interventionscores on a scale (Mean)
DRSP 3 mg/EE 20 µg (6 Cycles)6.7
DRSP 3 mg/EE 30 µg (6 Cycles)12.2

[back to top]

Distribution of Severity of Lumbago During Menstruation at Cycle 13

Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities). (NCT00461305)
Timeframe: Up to Cycle 13 (364 days) with 28 days per cycle

Interventionparticipants (Number)
nonemildmoderatesevere
DRSP 3 mg/EE 20 µg (13 Cycles)14872193

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1175.7
Drospirenone (DRSP)/Ethinylestradiol (EE)1256.1

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1500.3
Drospirenone (DRSP)/Ethinylestradiol (EE)1316.1

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1486.6
Drospirenone (DRSP)/Ethinylestradiol (EE)1435.9

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1460.5
Drospirenone (DRSP)/Ethinylestradiol (EE)1454.7

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1469.8
Drospirenone (DRSP)/Ethinylestradiol (EE)1378.4

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1122.8
Drospirenone (DRSP)/Ethinylestradiol (EE)1345.0

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.8
Drospirenone (DRSP)/Ethinylestradiol (EE)41.8

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.6
Drospirenone (DRSP)/Ethinylestradiol (EE)43.1

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)58.7
Drospirenone (DRSP)/Ethinylestradiol (EE)39.8

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.8
Drospirenone (DRSP)/Ethinylestradiol (EE)39.7

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.4
Drospirenone (DRSP)/Ethinylestradiol (EE)43.2

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.5
Drospirenone (DRSP)/Ethinylestradiol (EE)42.3

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)41.7
Drospirenone (DRSP)/Ethinylestradiol (EE)41.5

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)68.1
Drospirenone (DRSP)/Ethinylestradiol (EE)54.1

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.4
Drospirenone (DRSP)/Ethinylestradiol (EE)45.9

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)64.0
Drospirenone (DRSP)/Ethinylestradiol (EE)43.7

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)61.5
Drospirenone (DRSP)/Ethinylestradiol (EE)45.9

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)67.5
Drospirenone (DRSP)/Ethinylestradiol (EE)51.8

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)67.4
Drospirenone (DRSP)/Ethinylestradiol (EE)46.4

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)50.3
Drospirenone (DRSP)/Ethinylestradiol (EE)47.1

[back to top]

Mean Neural Tube Defect (NTD) Risk Reduction at Week 24

The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline (NCT00468481)
Timeframe: Baseline and week 24

Interventionper 1000 birth (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.51
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.03

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)310.3
Drospirenone (DRSP)/Ethinylestradiol (EE)68.2

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)110.9
Drospirenone (DRSP)/Ethinylestradiol (EE)-37.6

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)452.7
Drospirenone (DRSP)/Ethinylestradiol (EE)64.6

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)448.9
Drospirenone (DRSP)/Ethinylestradiol (EE)68.0

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 8

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 8

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)0

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 4

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 4

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)0
Drospirenone (DRSP)/Ethinylestradiol (EE)0

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 24

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 24

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.3
Drospirenone (DRSP)/Ethinylestradiol (EE)0.1

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 20

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 20

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.2

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 16

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 16

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.1

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 12

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 12

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.3
Drospirenone (DRSP)/Ethinylestradiol (EE)0

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 8

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)18.4
Drospirenone (DRSP)/Ethinylestradiol (EE)2.2

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)15.2
Drospirenone (DRSP)/Ethinylestradiol (EE)0.6

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)15.1
Drospirenone (DRSP)/Ethinylestradiol (EE)-1.6

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)17.6
Drospirenone (DRSP)/Ethinylestradiol (EE)2.4

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)17.6
Drospirenone (DRSP)/Ethinylestradiol (EE)0.3

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1365.2
Drospirenone (DRSP)/Ethinylestradiol (EE)967.6

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1412.7
Drospirenone (DRSP)/Ethinylestradiol (EE)1407.6

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)910.9
Drospirenone (DRSP)/Ethinylestradiol (EE)915.1

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1308.9
Drospirenone (DRSP)/Ethinylestradiol (EE)1025.2

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1419.8
Drospirenone (DRSP)/Ethinylestradiol (EE)981.3

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1355.3
Drospirenone (DRSP)/Ethinylestradiol (EE)949.2

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1007.1
Drospirenone (DRSP)/Ethinylestradiol (EE)889.5

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1184.8
Drospirenone (DRSP)/Ethinylestradiol (EE)970.4

[back to top]

Plasma Folate Level at 24 Weeks

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: Week 24

Interventionnmol/L (Least Squares Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.55
Drospirenone (DRSP)/Ethinylestradiol (EE)41.67

[back to top]

Red Blood Cell (RBC) Folate Level at 24 Weeks

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: Week 24

Interventionnmol/L (Least Squares Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1406.91
Drospirenone (DRSP)/Ethinylestradiol (EE)1022.21

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)405.8
Drospirenone (DRSP)/Ethinylestradiol (EE)86.5

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 4

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)73.4
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)66.1
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)86.3

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 3

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)78.6
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)79.2
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)84.6

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 2

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)85.9
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)84.7
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)86.7

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 14

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. There were no participants who received treatment in cycle 14 in the Flexible (extended) regimen no.1 of EE20/DRSP (BAY86-5300). There were no participants who provided bleeding data for cycle 14 in the Flexible (extended) regimen no.2 of EE20/DRSP (BAY86-5300), although one woman did receive 14 cycles of treatment. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)9.1

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 13

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. There were no participants who provided bleeding data for cycle 13 in the Flexible (extended) regimen no.1 of EE20/DRSP (BAY86-5300), although one women did receive 13 cycles of treatment. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)0
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)20.5

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 11

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)55.6
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)62.5
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)85.9

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 10

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)78.9
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)70.0
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)84.6

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 1

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)84.2
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)83.8
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)66.8

[back to top]

Pearl Index

The Pearl Index (PI) is the number of pregnancies per 100 woman years. The PI is obtained by dividing the number of pregnancies during treatment (conception date on/after the 1st day of treatment and not later than last day of treatment +14 days) by the treatment exposure time (in 100 women years) that the women were under risk of getting pregnant. The Pearl Index was not calculated individually for either the Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300) treatment arm, nor for the Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300) treatment arm, because the low sample size in these treatment arms (approximately. 200 subjects per group) did not allow a reliable PI calculation of these groups alone. (NCT00567164)
Timeframe: Up to 1 year

InterventionPregnancies per 100 years of exposure (Mean)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)1.65
Pooled Analysis of Flexible Regimen no. 1 and Regimen no. 21.92

[back to top]

Number of Bleeding Days (Including Spotting Days)

Number of days per participant with bleeding or spotting (NCT00567164)
Timeframe: Up to 1 year

InterventionDays (Mean)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)39.9
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)46.8
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)51.8

[back to top]

Number of Bleeding Days (Excluding Spotting Days)

Number of days per participant with bleeding (excluding spotting days) (NCT00567164)
Timeframe: Up to 1 year

InterventionDays (Mean)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)19.4
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)21.4
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)32.9

[back to top]

Length of Cycles

Cycle length per cycle. For the flexible and stop and go extended treatment arms, a treatment cycle started with the first day of pill intake after a tablet-free interval and ended with the last day of the subsequent tablet-free interval. A tablet-free interval (treatment withdrawal) was defined as at least 3 consecutive days without tablet intake. For the standard 24+4 treatment arm, a new cycle started each time a new blister pack of medication was started. (NCT00567164)
Timeframe: Up to 1 year

InterventionDays (Mean)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)70.9
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)67.6
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)28.8

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 12

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)0
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)33.3
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)78.6

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 6

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)77.7
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)69.8
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)85.2

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 5

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)78.0
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)69.0
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)85.8

[back to top]

Number of Scheduled and Unscheduled Bleeding Days

Scheduled bleeding is any bleeding/spotting (bl/sp) that occurs during the tablet free interval through the next 4 days of the subsequent treatment cycle. Unscheduled bleeding is any bl/sp that occurs while taking active hormones, except for bl/sp that occurs during the tablet free interval through day 4 of the subsequent treatment cycle or bl/sp on days 1-7 of treatment cycle 1. (NCT00567164)
Timeframe: Up to 1 year

,
InterventionDays (Mean)
Scheduled bleeding daysUnscheduled bleeding days
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)20.620.0
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)21.925.3

[back to top]

Number of Intracyclic Bleeding Days

Intracyclic bleeding was considered any bleeding/spotting that occurred between withdrawal bleedings. (NCT00567164)
Timeframe: Up to 1 year

,,
InterventionDays (Mean)
Including spotting only episodesExcluding spotting only episodes
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)7.15.2
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)8.03.6
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)14.47.3

[back to top]

Number of Days With Bleeding/ (Including and Excluding Spotting) Within 90-day Reference Period 4

Number of days per participant with bleeding (including and excluding spotting) within 90-day reference period 4. Reference period 4 (Day 271 to Day 360) was a 90-day period that started with the intake of study medication at the beginning of Cycle 10. (NCT00567164)
Timeframe: Day 271 to Day 360

,,
InterventionDays (Mean)
Including days with spottingExcluding days with spotting
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)13.68.4
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)9.04.2
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)9.54.0

[back to top]

Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 3

Number of days per participant with bleeding (including and excluding spotting) within 90-day reference period 3. Reference period 3 (Day 181 to Day 270) was a 90-day period that started with the intake of study medication at the beginning of Cycle 7. (NCT00567164)
Timeframe: Day 181 to Day 270

,,
InterventionDays (Mean)
Including days with spottingExcluding days with spotting
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)14.89.4
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)10.04.7
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)11.44.9

[back to top]

Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 2.

Number of days per participant with bleeding (including and excluding spotting) within 90-day reference period 2. Reference period 2 (Day 91 to Day 180) was a 90-day period that started with the intake of study medication at the beginning of Cycle 4. (NCT00567164)
Timeframe: Day 91 to Day 180

,,
InterventionDays (Mean)
Including days with spottingExcluding days with spotting
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)14.89.7
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)11.05.1
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)12.55.4

[back to top]

Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 1.

Number of days per participant with bleeding (including and excluding spotting) within 90-day reference period 1. Reference period 1 (Day 1 to Day 90) was a 90 day period starting with the initial intake of study medication (protocol-specified to occur on first day of menstrual or withdrawal bleeding after screening). Therefore, the first 90-day reference period contains additional bleeding days (associated with the menstrual cycle prior to the start of study medication) when compared to any other reference period. (NCT00567164)
Timeframe: Day 1 to Day 90

,,
InterventionDays (Mean)
Including days with spottingExcluding days with spotting
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)19.712.6
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)16.68.3
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)18.59.1

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 9

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)73.9
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)80.0
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)85.5

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 8

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)82.1
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)69.2
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)86.7

[back to top]

Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 7

A withdrawal bleeding episode (WBE) for the two flexible (extended) treatment arms 1) Ended at the earliest 4 days before the first day of the pill break of that cycle or later, AND 2) Started before or at the latest on the 4th day of the next cycle. For the conventional 24+4 treatment arm, a WBE 1) Started on or after Day 21 of that cycle, and lasted at least until Day 25 of the same cycle, OR 2) Started on or after Day 25 of that cycle, but before Day 25 of the next cycle. If more than one episode satisfied the above criteria, the first episode to occur was considered to be the WBE. (NCT00567164)
Timeframe: Up to 1 year

InterventionPercentage of Participants (Number)
Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)78.3
Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)70.0
Conventional Regimen of EE20/DRSP (YAZ, BAY86-5300)84.0

[back to top]

Percent Change in Daily Record of Severity of Problems (DRSP)

The DRSP is a 24-item self-administered daily dairy that assesses the severity of mood and physical symptoms which occur as part of the premenstrual syndrome and PMDD. Each question is rated on a scale of 1-6 with a total score range from 24-144. A higher score indicates greater symptom burden. (NCT00633360)
Timeframe: Baseline and 2 months

Interventionpercent change (Median)
Drospirenone and Ethinyl Estradiol-23.5
Placebo-20.9

[back to top]

Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS)

The Montgomery-Åsberg Depression Rating Scale is a widely used 10-item clinician-rated scale that describes the severity of depressive symptoms. It has a range of 0-60 with higher scores indicating greater symptom burden. Participants were assessed at baseline and during 2nd treatment month in order to calculate the change in MADRS score. (NCT00633360)
Timeframe: Baseline and 2 months

Interventionpercent change (Median)
Drospirenone and Ethinyl Estradiol-43.6
Placebo-38.9

[back to top]

Adiponectin at Baseline and 6 Months

Adiponectin was measured by radioimmunoassay. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionug/mL (Mean)
Adiponectin, BaselineAdiponectin, 6 months
Drospirenone/Ethinyl Estradiol5.96.7
Rosiglitazone6.511.6

[back to top]

Cholesterol at Baseline and 6 Months

Cholesterol was measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
Cholesterol, BaselineCholesterol, 6 months
Drospirenone/Ethinyl Estradiol156.5185.2
Rosiglitazone149.5146.2

[back to top]

Delta 17-OHProg at Baseline and 6 Months

Delta 17-OHProg (17-hydroxyprogesterone) was measured by HPLC-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/dL (Mean)
Delta 17-OHProg, BaselineDelta 17-OHProg, 6 months
Drospirenone/Ethinyl Estradiol169.8175.4
Rosiglitazone207.0178.0

[back to top]

Delta Androstenedione at Baseline and 6 Months

Delta Androstenedione was measured by HPLC-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/dL (Mean)
Delta Androstenedione, BaselineDelta Androstenedione, 6 months
Drospirenone/Ethinyl Estradiol82.6117.0
Rosiglitazone79.258.4

[back to top]

Delta DHEA at Baseline and 6 Months

Delta DHEA was measured by HPLC-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionug/dL (Mean)
Delta DHEA, BaselineDelta DHEA, 6 months
Drospirenone/Ethinyl Estradiol1001.61092.1
Rosiglitazone817.4643.4

[back to top]

DHEAS at Baseline and 6 Months

DHEAS (dehydroepiandrosterone sulfate) was measured by radioimmunoassay in dilute serum after hydrolysis. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionug/dL (Mean)
DHEAS, BaselineDHEAS, 6 months
Drospirenone/Ethinyl Estradiol212.2197.5
Rosiglitazone165.4160.9

[back to top]

Free Testosterone at Baseline and 6 Months

Free testosterone was measured by equilibrium dialysis. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionpg/mL (Mean)
Free Testosterone, BaselineFree Testosterone, 6 months
Drospirenone/Ethinyl Estradiol7.51.9
Rosiglitazone10.77.7

[back to top]

Glucose Tolerance Status at Baseline and 6 Months.

Glucose tolerance status was classified according to the ADA (American Diabetes Association) criteria. (NCT00640224)
Timeframe: Baseline and 6 months

,
InterventionParticipants (Count of Participants)
Normal glucose tolerance, baselineImpaired glucose tolerance, baselineNormal glucose tolerance, 6 monthsImpaired glucose tolerance, 6 months
Drospirenone/Ethinyl Estradiol128137
Rosiglitazone152152

[back to top]

HDL at Baseline and 6 Months

HDL (high-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
HDL, BaselineHDL, 6 months
Drospirenone/Ethinyl Estradiol40.955.0
Rosiglitazone42.746.1

[back to top]

Hepatic Insulin Sensitivity at Baseline and 6 Months.

Hepatic insulin sensitivity was evaluated prior to the hyperinsulinemic-euglycemic clamp. (NCT00640224)
Timeframe: Baseline and 6 months

,
Intervention(mg/kg/min x uU/mL)-1 (Mean)
Hepatic insulin sensitivity, BaselineHepatic insulin sensitivity, 6 months
Drospirenone/Ethinyl Estradiol17.416.8
Rosiglitazone17.324.1

[back to top]

Hs-CRP at Baseline and 6 Months

hs-CRP(high-sensitivity C-reactive protein) was measured by COAG-Nephelometry. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/L (Mean)
hs-CRP, Baselinehs-CRP, 6 months
Drospirenone/Ethinyl Estradiol1.73.8
Rosiglitazone2.12.2

[back to top]

LDL at Baseline and 6 Months

LDL (low-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
LDL, BaselineLDL, 6 months
Drospirenone/Ethinyl Estradiol85.997.7
Rosiglitazone85.484.3

[back to top]

Leptin at Baseline and 6 Months

Leptin was measured by radioimmunoassay. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/mL (Mean)
Leptin, BaselineLeptin, 6 months
Drospirenone/Ethinyl Estradiol40.646.8
Rosiglitazone43.842.7

[back to top]

Morning Blood Pressure at Baseline and 6 Months

Morning blood pressure was measured with an automated sphygmomanometer. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmm Hg (Mean)
Morning Systolic BP, BaselineMorning Diasytolic BP, BaselineMorning Systolic BP, 6 monthsMorning Diastolic BP, 6 months
Drospirenone/Ethinyl Estradiol108.558.1112.259.5
Rosiglitazone108.258.1107.558.7

[back to top]

Non-HDL Cholesterol at Baseline and 6 Months

Non-HDL cholesterol was measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
Non-HDL cholesterol, BaselineNon-HDL cholesterol, 6 months
Drospirenone/Ethinyl Estradiol70.687.6
Rosiglitazone65.362.3

[back to top]

Percent Body Fat at Baseline and 6 Months

DXA scans were done to measure the percentage of body fat. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionpercentage of body fat (Mean)
Percent body fat, BaselinePercent body fat, 6 months
Drospirenone/Ethinyl Estradiol47.348.2
Rosiglitazone46.246.6

[back to top]

Peripheral Insulin Sensitivity at Baseline and 6 Months.

Peripheral insulin sensitivity was evaluated during the hyperinsulinemic-euglycemic clamp. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/kg/min per uU/mL (Mean)
Peripheral insulin sensitivity, BaselinePeripheral insulin sensitivity, 6 months
Drospirenone/Ethinyl Estradiol2.12.0
Rosiglitazone2.23.2

[back to top]

SHBG at Baseline and 6 Months

SHBG (sex hormone-binding globulin) was measured by immunoradiometric assay. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionnmol/L (Mean)
SHBG, BaselineSHBG, 6 months
Drospirenone/Ethinyl Estradiol22.7154.5
Rosiglitazone28.137.0

[back to top]

Total Fat Mass at Baseline and 6 Months

DXA (dual-energy x-ray absorptiometry) scans were done to measure total fat mass. (NCT00640224)
Timeframe: Baseline and 6 months

,
InterventionKg (Mean)
Fat mass, BaselineFat mass, 6 months
Drospirenone/Ethinyl Estradiol48.049.1
Rosiglitazone44.545.4

[back to top]

Night Blood Pressure at Baseline and 6 Months

Night blood pressure was measured with an automated sphygmomanometer. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmm Hg (Mean)
Night Systolic BP, BaselineNight Diastolic BP, BaselineNight Systolic BP, 6 monthsNight Diastolic BP, 6 months
Drospirenone/Ethinyl Estradiol112.958.6116.962.6
Rosiglitazone117.563.0115.261.7

[back to top]

Triglycerides at Baseline and 6 Months

Triglycerides were measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
Triglycerides, BaselineTriglycerides, 6 months
Drospirenone/Ethinyl Estradiol148.4163.5
Rosiglitazone106.779.2

[back to top]

Delta 17-OHPreg at Baseline and 6 Months

Delta 17-OHPreg (17-hydroxypregnenolone) was measured by HPLC-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/dL (Mean)
Delta 17-OHPreg, BaselineDelta 17-OHPreg, 6 months
Drospirenone/Ethinyl Estradiol1024.31088.9
Rosiglitazone912.8914.7

[back to top]

Total Testosterone at Baseline and 6 Months

Total testosterone was measured by HPLC(high-performance liquid chromatography)-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/dL (Mean)
Total Testosterone, BaselineTotal Testosterone, 6 months
Drospirenone/Ethinyl Estradiol34.530.6
Rosiglitazone45.736.9

[back to top]

Percent Change in Truncal Lesion Counts

Acne lesion count (noninflammatory, inflammatory and total lesions) difference between week 0 (baseline) and week 24 is divided by the acne lesion count at week 0 and multiplied by 100. A positive change indicates a decrease in truncal acne lesions. (NCT00722761)
Timeframe: 0-24 weeks

,
Interventionpercentage change of lesions (Mean)
Noninflammatory lesionsInflammatory lesionsTotal acne lesions
Drosperinone and Ethinyl Estradiol52.153.251.8
Placebo Tablet-9.218.217

[back to top]

Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination

Percentage of subjects rated Clear (score 0) or Almost Clear (score 1) on the Investigator's Global Assessment (IGA) of truncal acne at Week 24 as well as Subject's Assessment of Acne at Week 24/Early Termination were taken. It was computed by: number of successes (those scored 0 or 1)divided by the number of participants multiplied by 100. (NCT00722761)
Timeframe: 24 weeks

,
Interventionpercentage of participants (Number)
Investigator Global Assessment IGASubject Assessment SGA
Drosperinone and Ethinyl Estradiol53.360
Placebo Tablet2080

[back to top]

Mean Improvement in the Sartorius Severity Score at Month 6.

The Sartorius Severity score reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease. (NCT00722800)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Drospirenone and Ethinyl Estradiol (YAZ)-3.5
Placebo Tablets12

[back to top]

Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Month 6.

Dermatology Life Quality Index (DLQI) Score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. The DLQI score ranges from 0 (best) to 30 (worst). (NCT00722800)
Timeframe: 6 months

Interventionpoints (Mean)
Drospirenone and Ethinyl Estradiol (YAZ)3
Placebo Tablets8.5

[back to top]

Change From Baseline in VAS Pain Scale at Month 6.

"For this pain assessment, the participant indicated the level of average pain experienced over the past 24 hours on a horizontal line, 10 cm in length. A score of 0 indicated no pain and a score of 10 indicated worst pain. The value indicates the change from the baseline participant assessment on the 0 to 10 scale. A negative value indicates a reduction in pain intensity." (NCT00722800)
Timeframe: 6 months from Baseline

Interventionunits on a scale (Mean)
Drospirenone and Ethinyl Estradiol (YAZ)-2.25
Placebo Tablets2

[back to top]

Number of Days of Total Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. (NCT00745901)
Timeframe: Cycle 1 (Day 8 to Day 28)

InterventionDays (Mean)
NGM/25mcg EE6.2
DRSP/20mcg EE5.2

[back to top]

Number of Days of Total Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. (NCT00745901)
Timeframe: Cycle 2 (day 29 to Day 56)

InterventionDays (Mean)
NGM/25mcg EE5.3
DRSP/20mcg EE4.6

[back to top]

Number of Days of Total Blood Loss - Cycle 3

cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. (NCT00745901)
Timeframe: Cycle 3 (Day 57 to Day 84)

InterventionDays (Mean)
NGM/25mcg EE4.6
DRSP/20mcg EE3.6

[back to top]

Number of Days of Unscheduled Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE1.9
DRSP/20mcg EE2.0

[back to top]

Number of Days of Unscheduled Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE1.3
DRSP/20mcg EE1.9

[back to top]

Number of Days of Unscheduled Blood Loss - Cycle 3

Number of Days of Unscheduled Blood Loss - Cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE1.4
DRSP/20mcg EE2.4

[back to top]

Number of Participants With Breakthrough Bleeding/Spotting Cycle 1

Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding. (NCT00745901)
Timeframe: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE53
DRSP/20mcg EE56

[back to top]

Number of Participants With Breakthrough Bleeding/Spotting Cycle 2

Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding. (NCT00745901)
Timeframe: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE39
DRSP/20mcg EE62

[back to top]

Number of Participants With Breakthrough Bleeding/Spotting Cycle 3

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE47
DRSP/20mcg EE74

[back to top]

Number of Participants With Unscheduled Bleeding Cycle 1

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE72
DRSP/20mcg EE74

[back to top]

Number of Participants With Unscheduled Bleeding Cycle 2

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE57
DRSP/20mcg EE87

[back to top]

Number of Participants With Unscheduled Bleeding Cycle 3

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE65
DRSP/20mcg EE94

[back to top]

Overall Number of Days of Scheduled Blood Loss

summary of the overall number of days of scheduled blood loss. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen. (NCT00745901)
Timeframe: Cycle 1 to Cycle 3 (Day 8 to Day 84)

InterventionDays (Mean)
NGM/25mcg EE11.2
DRSP/20mcg EE7.0

[back to top]

Overall Number of Days of Total Blood Loss

cycle control between treatment groups, overall. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. (NCT00745901)
Timeframe: Cycle 1 to 3 (Day 8 to Day 84)

InterventionDays (Mean)
NGM/25mcg EE15.8
DRSP/20mcg EE13.2

[back to top]

Overall Number of Days of Unscheduled Blood Loss

cycle control between treatment groups, for three 28-day cycles. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 1 to Cycle 3 (Day 8 to Day 80)

InterventionDays (Mean)
NGM/25mcg EE4.6
DRSP/20mcg EE6.1

[back to top]

Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes

Unscheduled blood loss episodes are bounded on both sides by at least 1 non- bleeding day. (NCT00745901)
Timeframe: Cycle 1 to Cycle 3 (Day 8 to Day 80)

,
InterventionParticipants (Number)
0 Episode1 Episode2 Episodes3 Episodes4 Episodes5 Episodes6 Episodes8 Episodes9 Episodes
DRSP/20mcg EE29415022118231
NGM/25mcg EE55462321137000

[back to top]

Patient Satisfaction - Overall

patient satisfaction based on 5 questions during three 28-day cycles - Question 1 (Overall Satisfaction). On a scale of 1 to 5 where 1=Very satisfied and 5=Very dissatisfied. (NCT00745901)
Timeframe: Cycle 1 to Cycle 3

,
InterventionParticipants (Number)
Number of responses1. Very Satisfied2. Somewhat satisfied3. Neither satisfied or dissatisfied4. Dissatisfied5. Very dissatisfied
DRSP/20mcg EE16211532681
NGM/25mcg EE159993512112

[back to top]

Number of Days of Scheduled Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen. (NCT00745901)
Timeframe: Cycle 1 (Day 22 to 32 for NGM/25mcg EE and day 25 to 32 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE4.3
DRSP/20mcg EE3.2

[back to top]

Number of Days of Scheduled Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen. (NCT00745901)
Timeframe: Cycle 2 (Day 50 to 60 for NGM/25mcg EE and day 53 to 60 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE4.0
DRSP/20mcg EE2.8

[back to top]

Number of Days of Scheduled Blood Loss - Cycle 3

cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen. (NCT00745901)
Timeframe: Cycle 3 (Day 78 to 84 for NGM/25mcg EE and day 81 to 84 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE3.1
DRSP/20mcg EE1.2

[back to top]

Percent Change From Cycle 6 to Baseline in Inflammatory Lesion Count (Papules, Pustules, and Nodules), Non-inflammatory Lesion Count

Acne lesions were counted by the trained designee over the entire face. All types of lesions were to be identified and separately counted, i.e., non-inflammatory open and closed comedones, and inflammatory papules, pustules, and nodules. The percent change from Cycle 6 to Baseline was calculated as (lesion count at Baseline - lesion count at Cycle 6)/(lesion count at Baseline)*100, so that improvement is indicated by a larger percent change. (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline

,
InterventionPercent change (Mean)
Inflammatory lesion countNon-inflammatory lesion count
EE20/Drospirenone (YAZ, BAY86-5300)75.4969.27
Placebo60.8850.24

[back to top]

"Percentage of Participants Classified as Improved According to the Investigator's Overall Improvement Rating and on the Participant's Overall Self-Assessment Rating"

"The proportion of participants rated as improved comprises those with complete remission, excellent, marked, or moderate improvement according to the Investigator's Overall Improvement Rating and those with excellent, good, or fair improvement the Participant's Overall Self-Assessment Rating. No improvement or deterioration (worsening of disease signs and symptoms compared to Baseline in the view of investigator/subject) comprise not improved status." (NCT00818519)
Timeframe: At Cycle 6 (Day 15±3 days of Treatment Cycle 6, 28 days per cycle)

,
InterventionPercentage of participants (Number)
InvestigatorParticipant
EE20/Drospirenone (YAZ, BAY86-5300)93.794.9
Placebo78.184.9

[back to top]

Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the PPS (Per Protocol Set)

Acne lesions were counted by the trained designee over the entire face. All types of lesions were to be identified and separately counted, i.e., non-inflammatory open and closed comedones, and inflammatory papules, pustules, and nodules. The percent change from Cycle 6 to Baseline was calculated as (total lesion count at Baseline - total lesion count at Cycle 6)/(total lesion count at Baseline)*100, so that improvement is indicated by a larger percent change. (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline

InterventionPercent change (Mean)
EE20/Drospirenone (YAZ, BAY86-5300)72.63
Placebo55.56

[back to top]

Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the FAS (Full Analysis Set)

Acne lesions were counted by the trained designee over the entire face. All types of lesions were to be identified and separately counted, i.e., non-inflammatory open and closed comedones, and inflammatory papules, pustules, and nodules. The percent change from Cycle 6 to Baseline was calculated as (total lesion count at Baseline - total lesion count at Cycle 6)/(total lesion count at Baseline)*100, so that improvement is indicated by a larger percent change. (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline

InterventionPercent change (Mean)
EE20/Drospirenone (YAZ, BAY86-5300)66.79
Placebo37.71

[back to top]

Percent Change From Cycle 6 to Baseline in Lesion Count of Pustules

Acne lesions were counted by the trained designee over the entire face. All pustules were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (pustule count at Baseline - pustule count at Cycle 6)/(pustule count at Baseline)*100, so that improvement is indicated by a larger percent change. (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline

InterventionPercent change (Mean)
EE20/Drospirenone (YAZ, BAY86-5300)79.88
Placebo78.15

[back to top]

Percent Change From Cycle 6 to Baseline in Lesion Count of Papules

Acne lesions were counted by the trained designee over the entire face. All papules were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (papule count at Baseline - papule count at Cycle 6)/(papule count at Baseline)*100, so that improvement is indicated by a larger percent change. (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline

InterventionPercent change (Mean)
EE20/Drospirenone (YAZ, BAY86-5300)72.36
Placebo55.03

[back to top]

Percent Change From Cycle 6 to Baseline in Lesion Count of Open Comedones

Acne lesions were counted by the trained designee over the entire face. All open comedones were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (open comedone count at Baseline -open comedone count at Cycle 6)/(open comedone count at Baseline)*100, so that improvement is indicated by a larger percent change. (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline

InterventionPercent change (Mean)
EE20/Drospirenone (YAZ, BAY86-5300)24.03
Placebo38.31

[back to top]

"Percentage of Participants Classified as 0 or 1 on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 1"

ISGA scale 0: Normal, clear skin with no evidence of acne vulgaris; 1: Skin is almost clear: few non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving, not pink-red), no nodular lesions; 2: Few inflammatory lesions, little inflammation, some comedones, no nodular lesions; 3: Non-inflammatory lesions predominate, several inflammatory lesions, one small nodular lesion maybe present; 4: Many inflammatory lesions, up to many comedones, up to a few nodular lesions; 5: Numerous highly inflammatory lesions predominate, many papules and pustules or nodular lesions (NCT00818519)
Timeframe: Cycle 1 (Day 15±3 days of Treatment Cycle 1)

InterventionPercentage of participants (Number)
EE20/Drospirenone (YAZ, BAY86-5300)1.2
Placebo0.0

[back to top]

"Percentage of Participants Classified as 0 or 1 on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 3"

ISGA scale 0: Normal, clear skin with no evidence of acne vulgaris; 1: Skin is almost clear: few non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving, not pink-red), no nodular lesions; 2: Few inflammatory lesions, little inflammation, some comedones, no nodular lesions; 3: Non-inflammatory lesions predominate, several inflammatory lesions, one small nodular lesion maybe present; 4: Many inflammatory lesions, up to many comedones, up to a few nodular lesions; 5: Numerous highly inflammatory lesions predominate, many papules and pustules or nodular lesions (NCT00818519)
Timeframe: Cycle 3 (Day 15±3 days of Treatment Cycle 3)

InterventionPercentage of participants (Number)
EE20/Drospirenone (YAZ, BAY86-5300)2.5
Placebo4.9

[back to top]

"Percentage of Participants Classified as 0 or 1 on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 6"

ISGA scale 0: Normal, clear skin with no evidence of acne vulgaris; 1: Skin is almost clear: few non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving, not pink-red), no nodular lesions; 2: Few inflammatory lesions, little inflammation, some comedones, no nodular lesions; 3: Non-inflammatory lesions predominate, several inflammatory lesions, one small nodular lesion maybe present; 4: Many inflammatory lesions, up to many comedones, up to a few nodular lesions; 5: Numerous highly inflammatory lesions predominate, many papules and pustules or nodular lesions (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6)

InterventionPercentage of participants (Number)
EE20/Drospirenone (YAZ, BAY86-5300)49.3
Placebo18.3

[back to top]

"Percentage of Participants Classified as 0 or 1 on the 6-point ISGA (Investigator Static Global Assessment) Scale at Screening Visit"

ISGA scale 0: Normal, clear skin with no evidence of acne vulgaris; 1: Skin is almost clear: few non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving, not pink-red), no nodular lesions; 2: Few inflammatory lesions, little inflammation, some comedones, no nodular lesions; 3: Non-inflammatory lesions predominate, several inflammatory lesions, one small nodular lesion maybe present; 4: Many inflammatory lesions, up to many comedones, up to a few nodular lesions; 5: Numerous highly inflammatory lesions predominate, many papules and pustules or nodular lesions (NCT00818519)
Timeframe: Screening visit

InterventionPercentage of participants (Number)
EE20/Drospirenone (YAZ, BAY86-5300)0.0
Placebo0.0

[back to top]

Percent Change From Cycle 6 to Baseline in Lesion Count of Closed Comedones

Acne lesions were counted by the trained designee over the entire face. All closed comedones were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (closed comedone count at Baseline - closed comedone count at Cycle 6)/(closed comedone count at Baseline)*100, so that improvement is indicated by a larger percent change. (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline

InterventionPercent change (Mean)
EE20/Drospirenone (YAZ, BAY86-5300)69.52
Placebo48.73

[back to top]

Percent Change From Cycle 6 to Baseline in Lesion Count of Nodules

Acne lesions were counted by the trained designee over the entire face. All nodules were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (nodule count at Baseline - nodule count at Cycle 6)/(nodule count at Baseline)*100, so that improvement is indicated by a larger percent change. (NCT00818519)
Timeframe: Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline

InterventionPercent change (Mean)
EE20/Drospirenone (YAZ, BAY86-5300)95.83
Placebo95.00

[back to top]

Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD)

This crossover study examined the effects of E+MPA versus E+DRSP on brachial artery reactivity (BAR) assessed after six weeks of treatment. BAR is a noninvasive measure of endothelium-dependent flow-mediated vasodilation (FMD) of the brachial artery. With this technique, inflation of an arm blood pressure cuff to suprasystolic blood pressure causes relative ischemia downstream to the cuff. Upon deflation, a brief state of increased blood flow occurs (reactive hyperemia), and the resulting increase in shear stress causes nitric oxide release and resulting vasodilation of the brachial artery (flow-mediated vasodilation). The flow-mediated changes in brachial artery diameter can be imaged by ultrasound and measured as an index of peripheral vasomotor function. BAR correlates with invasive assessments of coronary endothelial function as well as multiple cardiovascular risk factors. (NCT01109979)
Timeframe: %FMD after 6 weeks of treatment

Intervention% FMD after 6 weeks of treatment (Mean)
E+MPA5.49
E+DRSP3.39

[back to top]

AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Ethinyl Estradiol AUC0-inf. (NCT01182194)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)1236.96
YAZ® (Reference)1235.91

[back to top]

Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Ethinyl Estradiol Cmax. (NCT01182194)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)128.87
YAZ® (Reference)126.03

[back to top]

Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Drospirenone Cmax. (NCT01182194)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)67.69
YAZ® (Reference)74.33

[back to top]

AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Ethinyl Estradiol AUC0-t. (NCT01182194)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)1145.90
YAZ® (Reference)1155.31

[back to top]

AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Drospirenone AUC0-inf. (NCT01182194)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)866.91
YAZ® (Reference)884.24

[back to top]

AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Drospirenone AUC0-t. (NCT01182194)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)814.32
YAZ® (Reference)824.41

[back to top]

AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Drospirenone AUC0-inf. (NCT01182207)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)951.18
YAZ® (Reference)930.38

[back to top]

AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Drospirenone AUC0-t. (NCT01182207)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)889.67
YAZ® (Reference)867.10

[back to top]

AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Ethinyl Estradiol AUC0-t. (NCT01182207)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)1066.24
YAZ® (Reference)1079.54

[back to top]

Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Drospirenone Cmax. (NCT01182207)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)52.77
YAZ® (Reference)53.65

[back to top]

Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Ethinyl Estradiol Cmax. (NCT01182207)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)87.95
YAZ® (Reference)91.23

[back to top]

AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Ethinyl Estradiol AUC0-inf. (NCT01182207)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)1155.69
YAZ® (Reference)1175.76

[back to top]

Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation

The baseline uncorrected Cmax is a measure of the highest measured drug concentration including the endogenous L-5-methyl-THF level. It is obtained by collecting a series of blood samples and measuring the concentrations of L-5-methyl-THF in each sample. (NCT01253174)
Timeframe: up to 12 hours after administration

Interventionnmol/L (Geometric Mean)
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)65.2
L-5-MTHF Ca 0.451 mg (Metafolin)61.8

[back to top]

Time to Reach Maximum Concentration (Tmax) of L-5-methyl-THF

Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content (NCT01253174)
Timeframe: up to 12 hours after administration

Interventionhour (Median)
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)0.50
L-5-MTHF Ca 0.451 mg (Metafolin)0.50

[back to top]

Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation

The baseline corrected Cmax is a measure of the highest measured drug concentration provided solely by the treatment after subtracting endogenous L-5-methyl-THF level. It is obtained by collecting a series of blood samples, measuring the concentrations of L-5-methyl-THF in each sample and by subtracting the pre-treatment concentration. (NCT01253174)
Timeframe: up to 12 hours after administration

Interventionnmol/L (Geometric Mean)
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)51.7
L-5-MTHF Ca 0.451 mg (Metafolin)48.7

[back to top]

Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation

Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. (NCT01253174)
Timeframe: up to 96 hours after administration

Interventionpg/mL (Geometric Mean)
EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)58.5
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)61.6

[back to top]

Mean Maximum Concentration (Cmax) of DRSP Incl. Bioequivalence (BE) Evaluation

Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. (NCT01253174)
Timeframe: up to 168 hours after administration

Interventionng/mL (Geometric Mean)
EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)26.3
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)27.2

[back to top]

Mean Area Under the Concentration-time Curve From Administration up to 72h AUC(0-72h) of DRSP

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (NCT01253174)
Timeframe: up to 72 hours after administration

Interventionng∙h/mL (Geometric Mean)
EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)352
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)366

[back to top]

Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation

The baseline uncorrected AUC is a measure of the systemic drug exposure provided by the treatment including the endogenous L-5-methyl-THF level. It is obtained by collecting a series of blood samples and measuring the concentrations of L-5-methyl-THF in each sample. (NCT01253174)
Timeframe: up to 12 hours after administration

Interventionnmol∙h/L (Geometric Mean)
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)393
L-5-MTHF Ca 0.451 mg (Metafolin)390

[back to top]

Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation

The baseline corrected AUC is a measure of the systemic drug exposure provided by the treatment excluding the endogenous L-5-methyl-THF level. It is obtained by collecting a series of blood samples, measuring the concentrations of L-5-methyl-THF in each sample and by subtracting the pre-treatment concentration. (NCT01253174)
Timeframe: up to 12 hours after administration

Interventionnmol∙h/L (Geometric Mean)
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)236
L-5-MTHF Ca 0.451 mg (Metafolin)239

[back to top]

Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of EE Incl. Bioequivalence (BE) Evaluation

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (NCT01253174)
Timeframe: up to 96 hours after administration

Interventionpg∙h/mL (Geometric Mean)
EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)573
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)595

[back to top]

Mean Area Under the Concentration-time Curve (AUC) of DRSP Incl. Bioequivalence (BE) Evaluation

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (NCT01253174)
Timeframe: up to 168 hours after administration

Interventionng∙h/mL (Geometric Mean)
EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)433
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)447

[back to top]

Time to Reach Maximum Concentration (Tmax) of EE

Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content (NCT01253174)
Timeframe: up to 96 hours after administration

Interventionhour (Median)
EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)2.00
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)2.00

[back to top]

Time to Reach Maximum Concentration (Tmax) of DRSP

Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content (NCT01253174)
Timeframe: up to 168 hours after administration

Interventionhour (Median)
EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)1.50
EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)1.50

[back to top]

Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of DRSP Incl. Bioequivalence (BE) Evaluation

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (NCT01253187)
Timeframe: up to 168 hours after administration

Interventionng·h/mL (Geometric Mean)
EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)386
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)383

[back to top]

Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of EE Incl. Bioequivalence (BE) Evaluation

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (NCT01253187)
Timeframe: up to 96 hours after administration

Interventionpg·h/mL (Geometric Mean)
EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)358
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)370

[back to top]

Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation

The baseline corrected AUC is a measure of the systemic drug exposure provided by the treatment excluding the endogenous L-5-methyl-THF level. It is obtained by collecting a series of blood samples, measuring the concentrations of L-5-methyl-THF in each sample and by subtracting the pre-treatment concentration. (NCT01253187)
Timeframe: up to 12 hours after administration

Interventionnmol·h/L (Geometric Mean)
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)214
L-5-MTHF Ca 0.451 mg (Metafolin)217

[back to top]

Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation

The baseline uncorrected AUC is a measure of the systemic drug exposure provided by the treatment including the endogenous L-5-methyl-THF level. It is obtained by collecting a series of blood samples and measuring the concentrations of L-5-methyl-THF in each sample. (NCT01253187)
Timeframe: up to 12 hours after administration

Interventionnmol·h/L (Geometric Mean)
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)370
L-5-MTHF Ca 0.451 mg (Metafolin)370

[back to top]

Mean Maximum Concentration (Cmax) of DRSP Incl. Bioequivalence (BE) Evaluation

Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (NCT01253187)
Timeframe: up to 168 hours after administration

Interventionng/mL (Geometric Mean)
EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)25.4
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)26.7

[back to top]

Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation

Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (NCT01253187)
Timeframe: up to 96 hours after administration

Interventionpg/mL (Geometric Mean)
EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)39.6
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)41.9

[back to top]

Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation

The baseline corrected Cmax is a measure of the highest measured drug concentration provided solely by the treatment after subtracting endogenous L-5-methyl-THF level. It is obtained by collecting a series of blood samples, measuring the concentrations of L-5-methyl-THF in each sample and by subtracting the pre-treatment concentration. (NCT01253187)
Timeframe: up to 12 hours after administration

Interventionnmol/L (Geometric Mean)
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)44.3
L-5-MTHF Ca 0.451 mg (Metafolin)44.2

[back to top]

Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation

The baseline uncorrected Cmax is a measure of the highest measured drug concentration including the endogenous L-5-methyl-THF level. It is obtained by collecting a series of blood samples and measuring the concentrations of L-5-methyl-THF in each sample. (NCT01253187)
Timeframe: up to 12 hours after administration

Interventionnmol/L (Geometric Mean)
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)57.9
L-5-MTHF Ca 0.451 mg (Metafolin)57.7

[back to top]

Time to Reach Maximum Concentration (Tmax) of DRSP

Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content (NCT01253187)
Timeframe: up to 168 hours after administration

Interventionhours (Median)
EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)2.00
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)2.00

[back to top]

Time to Reach Maximum Concentration (Tmax) of EE

Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content (NCT01253187)
Timeframe: up to 96 hours after administration

Interventionhours (Median)
EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)1.50
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)1.52

[back to top]

Time to Reach Maximum Concentration (Tmax) of L-5-methyl-THF

Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content (NCT01253187)
Timeframe: up to 12 hours after administration

Interventionhours (Median)
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)0.50
L-5-MTHF Ca 0.451 mg (Metafolin)0.50

[back to top]

Mean Area Under the Concentration-time Curve From Administration up to 72h AUC(0-72h) of DRSP

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (NCT01253187)
Timeframe: up to 72 hours after administration

Interventionng·h/mL (Geometric Mean)
EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)350
EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)344

[back to top]

Folate Metabolite Pattern in Plasma at Cycle 6

Folate metabolite pattern in plasma at cycle 6 (NCT01258660)
Timeframe: week 24

,
Interventionnmol/L (Mean)
THF5,10-methenyl-THF
EE 0.03 mg/DRSP 3 mg (Yasmin) + Folic Acid5.761.95
EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo5.921.46

[back to top]

Homocysteine Concentrations in Plasma at Baseline and at the End of Treatment (Week 24) With Folic Acid

Homocysteine concentrations in plasma at baseline (median of baseline concentrations) and at the end of treatment (week 24) with folic acid (NCT01258660)
Timeframe: baseline, and up to 24 weeks of treatment

Interventionµmol/L (Mean)
baseline24 weeks
EE 0.03 mg/DRSP 3 mg (Yasmin) + Folic Acid9.27.6

[back to top]

Homocysteine Concentrations in Plasma at Baseline and at the End of Treatment (Week 24) With Metafolin

Homocysteine concentrations in plasma at baseline (median of baseline concentrations) and at the end of treatment (week 24) with Metafolin (NCT01258660)
Timeframe: baseline and week 24

Interventionµmol/L (Mean)
baseline24 weeks
EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo9.37.5

[back to top]

Proportion of Participants With RBC Folate Below 906 Nmol/L in the Yasmin + Metafolin Group in the Folate Elimination Phase (Week 24 to 44)

Proportion of participants with RBC folate below 906 nmol/L in the Yasmin + Metafolin group in the folate elimination phase (week 24 to 44) (NCT01258660)
Timeframe: from week 24 to week 44

Interventionproportion of participants (Number)
week 24week 26week 28week 30week 32week 34week 36week 38week 40week 42week 44
EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo0.0530.0670.1470.2130.4000.5330.7070.7600.8270.8670.907

[back to top]

Area Under the Curve (AUC) From Time 0 to 24 Weeks [AUC(0-24weeks)] for Plasma Folate and RBC (Red Blood Cell) Folate (Baseline Uncorrected)

The Area under the curve (AUC) is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. (NCT01258660)
Timeframe: up to 24 weeks of treatment

,
Interventionnmol·week/L (Geometric Mean)
plasma folateRBC folate
EE 0.03 mg/DRSP 3 mg (Yasmin) + Folic Acid90421876
EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo103024176

[back to top]

Area Under the Curve From Time 0 to 24 Weeks [AUC(0-24weeks)] for Plasma Folate and RBC (Red Blood Cell) Folate (Baseline Corrected)

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. (NCT01258660)
Timeframe: up to 24 weeks of treatment

,
Interventionnmol·week/L (Geometric Mean)
plasma folateRBC folate
EE 0.03 mg/DRSP 3 mg (Yasmin) + Folic Acid5618863
EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo64010427

[back to top]

Folate Metabolite Pattern in Plasma at Baseline

Folate metabolite pattern in plasma at baseline (NCT01258660)
Timeframe: pre-treatment

,
Interventionnmol/L (Mean)
Tetrahydrofolate (THF)5,10-methenyl-THF
EE 0.03 mg/DRSP 3 mg (Yasmin) + Folic Acid4.601.63
EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo4.071.57

[back to top]

Folate Metabolite Pattern in Plasma at Cycle 3

Folate metabolite pattern in plasma at cycle 3 (NCT01258660)
Timeframe: week 12

,
Interventionnmol/L (Mean)
THF5,10-methenyl-THF
EE 0.03 mg/DRSP 3 mg (Yasmin) + Folic Acid5.281.45
EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo4.981.76

[back to top]

Number of Pregnancies (Evaluable Cycles)

"Pearl index (PI) from Evaluable Cycles in non-breastfeeding women aged ≤ 35 years (at the time of trial enrollment).~The PI calculation was based on the following formula:~PI(evaluable cycles)= (∑ on-drug confirmed pregnancy ∈{exposure cycles})/(#{exposure cycles} ) X 1300" (NCT02269241)
Timeframe: up to 13 months

InterventionPearl Index (Number)
Drospirenone 4 mg2.9

[back to top]

Tolerability; Vaginal Bleeding Pattern

Vaginal bleeding pattern (NCT02269241)
Timeframe: up to 13 months

InterventionSubjects with bleeding (Number)
LF111 (Drospirenone)505

[back to top]

Pregnancy Ratio

Pregnancy ratio in women aged ≤ 35 years (at the time of trial enrollment) (NCT02269241)
Timeframe: up to 13 months

InterventionCumulative Pregnancy Rate (%) (Number)
LF111 (Drospirenone)2.46

[back to top]

Overall PI, PI for Method Failures

Overall PI, PI for method failures, PI (using evaluable cycles) and pregnancy ratio (life table analysis) in all women and in women up to 13 months (confirmed pregnancies) (NCT02269241)
Timeframe: up to 13 months

InterventionPearl Index (Number)
LF111 (Drospirenone)2.9

[back to top]

Number of Pregnancies (Method Failures)

PI for method failures in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies) (NCT02269241)
Timeframe: up to 13 months

InterventionPearl Index (Number)
LF111 (Drospirenone)3.4

[back to top]

Overall Pregnancies

Overall PI based on confirmed and on confirmed and suspected, non-confirmed pregnancies in total and by BMI and weight subgroups (NCT02269241)
Timeframe: up to 13 months

InterventionPearl Index (Number)
Pearl Index BMI<30Pearl Index BMI>=30Weight < MedianWeight >= Median
LF111 (Drospirenone)3.32.34.21.9

[back to top]

Number of Participants With Adverse Events as a Measure of Safety

Adverse events and changes in vital signs, clinical laboratory parameters (NCT02269241)
Timeframe: up to to 13 months

InterventionSubjects (Number)
LF111 (Drospirenone)667

[back to top]

Number of Pregnancies (All)

Pearl Index based on overall cycles (overall PI) in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies) (NCT02269241)
Timeframe: up to 13 months

InterventionPearl Index (Number)
LF111 (Drospirenone)2.7

[back to top]

Number of Pregnancies (by BMI and Weight)

PI for evaluable cycles in women aged ≤ 35 years in total and by BMI and weight subgroups based on confirmed and on confirmed and suspected, non-confirmed pregnancies (NCT02269241)
Timeframe: up to 13 months

InterventionPearl Index (Number)
Pearl Index BMI<30Pearl Index BMI>=30Weight < MedianWeight >= Median
LF111 (Drospirenone)4.12.95.12.3

[back to top]

Number of Subjects With Abnormal Physical Examination Results

"Physical examinations included an evaluation of body as a whole, skin, head, eyes, ears, nose, and throat, neck, cardiovascular, respiratory, musculoskeletal, neurologic, lymphatic/thyroid, abdomen.~When reporting the results of the physical examination, the use of the Abnormal category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the Normal category included Abnormal results that were not clinically significant, as well as no findings." (NCT02817828)
Timeframe: From screening to end of treatment (12 months)

InterventionParticipants (Count of Participants)
Body as a whole - Baseline72555016Body as a whole - EOT72555016Skin - Baseline72555016Skin - EOT72555016Head, Eyes, Ears, Nose and Throat - Baseline72555016Head, Eyes, Ears, Nose and Throat - EOT72555016Neck - Baseline72555016Neck - EOT72555016Cardiovascular - Baseline72555016Cardiovascular - EOT72555016Respiratory - Baseline72555016Respiratory - EOT72555016Musculoskeletal - Baseline72555016Musculoskeletal - EOT72555016Neurologic - Baseline72555016Neurologic - EOT72555016Lymphatic/Thyroid - Baseline72555016Lymphatic/Thyroid - EOT72555016Abdomen - Baseline72555016Abdomen - EOT72555016
AbnormalNot doneNormal
15 mg E4/3 mg DRSP1548
15 mg E4/3 mg DRSP5
15 mg E4/3 mg DRSP1493
15 mg E4/3 mg DRSP1537
15 mg E4/3 mg DRSP16
15 mg E4/3 mg DRSP1,476
15 mg E4/3 mg DRSP22
15 mg E4/3 mg DRSP1,543
15 mg E4/3 mg DRSP10
15 mg E4/3 mg DRSP1,492
15 mg E4/3 mg DRSP1,552
15 mg E4/3 mg DRSP0
15 mg E4/3 mg DRSP1,495
15 mg E4/3 mg DRSP1
15 mg E4/3 mg DRSP2
15 mg E4/3 mg DRSP1,551
15 mg E4/3 mg DRSP1,553
15 mg E4/3 mg DRSP1,549
15 mg E4/3 mg DRSP1,494
15 mg E4/3 mg DRSP3
15 mg E4/3 mg DRSP1,496

[back to top]

Number of Subjects With Abnormal Gynecological Examination Results

"Gynecological examinations included breast examination (performed by palpation) and assessment of the adnexa, cervix, uterus, vagina, and external genitalia.~When reporting the results, the use of the Abnormal category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the Normal category included Abnormal results that were not clinically significant, as well as no findings." (NCT02817828)
Timeframe: From screening to end of treatment (12 months)

InterventionParticipants (Count of Participants)
Breast - Baseline72555016Breast - EOT72555016Adnexa - Baseline72555016Adnexa - EOT72555016Cervix - Baseline72555016Cervix - EOT72555016Uterus - Baseline72555016Uterus - EOT72555016Vagina - Baseline72555016Vagina - EOT72555016External genitalia - Baseline72555016External genitalia - EOT72555016
AbnormalNormalNot done
15 mg E4/3 mg DRSP1,545
15 mg E4/3 mg DRSP8
15 mg E4/3 mg DRSP1,549
15 mg E4/3 mg DRSP4
15 mg E4/3 mg DRSP0
15 mg E4/3 mg DRSP1,496
15 mg E4/3 mg DRSP2
15 mg E4/3 mg DRSP1
15 mg E4/3 mg DRSP1,532
15 mg E4/3 mg DRSP21
15 mg E4/3 mg DRSP1,485
15 mg E4/3 mg DRSP13
15 mg E4/3 mg DRSP1,542
15 mg E4/3 mg DRSP11
15 mg E4/3 mg DRSP1,492
15 mg E4/3 mg DRSP6
15 mg E4/3 mg DRSP1,489
15 mg E4/3 mg DRSP1,552
15 mg E4/3 mg DRSP1,497

[back to top]

Endometrial Biopsy Histology at Screening and End of Treatment

Endometrial biopsies was obtained from a subset of subjects included in the endometrial safety substudy at the screening visit and at the end of treatment visit if the subject has completed at least 10 cycles. (NCT02817828)
Timeframe: Baseline and end of treatment (up to 13 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
Baseline72555016End of Treatment72555016
Menstrual typeSimple hyperplasia without atypiaComplex hyperplasia without atypiaPre-malignant/Malignant histologyNo tissueTissue insufficient for diagnosisBenign histology:AtrophicBenign histology: InactiveBenign histology:ProliferativeSecretory
15 mg E4/3 mg DRSP1
15 mg E4/3 mg DRSP2
15 mg E4/3 mg DRSP7
15 mg E4/3 mg DRSP76
15 mg E4/3 mg DRSP0
15 mg E4/3 mg DRSP9
15 mg E4/3 mg DRSP11
15 mg E4/3 mg DRSP61
15 mg E4/3 mg DRSP22
15 mg E4/3 mg DRSP5

[back to top]

Number of Unscheduled Spotting Days Per Cycle

Unscheduled spotting is defined as any spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting. (NCT02817828)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionDays (Mean)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP0.80.50.50.50.50.40.40.40.40.40.30.4

[back to top]

Number of Unscheduled Bleeding Days Per Cycle

Unscheduled bleeding is defined as any bleeding that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting. (NCT02817828)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionDays (Mean)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP0.20.10.10.20.10.10.10.10.10.10.10.1

[back to top]

Number of Subjects With Unscheduled Bleeding/Spotting

Unscheduled bleeding/spotting is defined as any bleeding/spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding. (NCT02817828)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP354282250249238207170202182168155154

[back to top]

Number of Subjects With Absence of Scheduled Bleeding and/or Spotting

Scheduled bleeding/spotting is defined as any bleeding/spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle. (NCT02817828)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP84901058391919010392898094

[back to top]

Number of Scheduled Bleeding and/or Spotting Days Per Cycle

Scheduled bleeding and /or spotting is defined as any bleeding and/or spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle. (NCT02817828)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionDays (Mean)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP6.15.35.25.04.94.94.74.84.74.64.74.6

[back to top]

Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)

"The MDQ is a standard method for measuring cyclical perimenstrual symptoms. The participants rated common symptoms and feelings associated with menstruation using the following scale: 0 (no experience of symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong),and 4 (present, severe) observed during pre-menstrual (4 days before menstruation), menstrual (most recent flow) and intermenstrual (remainder of the cycle) phases.~Reported values are values at Cycle 13 minus values at Baseline. An overall positive change from baseline represents an increase in symptom or feeling severity." (NCT02817828)
Timeframe: Baseline and Cycle 13 (1 cycle = 28 days)

,,
Interventionunits on a scale (Mean)
PainWater retentionAutonomic reactionsNegative affectImpaired concentrationBehaviour changeArousalControl
15 mg E4/3 mg DRSP Tablet - Intermenstrual Phase-0.10.0-0.0-0.10.0-0.0-0.30.0
15 mg E4/3 mg DRSP Tablet - Menstrual Phase-0.4-0.1-0.1-0.40.0-0.1-0.30.0
15 mg E4/3 mg DRSP Tablet - Premenstrual Phase-0.1-0.1-0.0-0.3-0.0-0.1-0.30.0

[back to top]

The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years)

On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred. (NCT02817828)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionMethod Failure Pearl Index (Number)
15 mg E4/3 mg DRSP0.25

[back to top]

The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years)

"On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation.~At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred." (NCT02817828)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionPearl Index (Number)
15 mg E4/3 mg DRSP0.41

[back to top]

The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening

"On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation.~At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred." (NCT02817828)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionPearl Index (Number)
15 mg E4/3 mg DRSP0.47

[back to top]

Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)

"The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good.~A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score).~In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate satisfaction with medicine and overall life satisfaction over the past week." (NCT02817828)
Timeframe: Baseline and Cycle 13 (1 cycle = 28 days)

InterventionPercentage maximum score on a scale (Mean)
15 mg E4/3 mg DRSP - Baseline Results73.4
15 mg E4/3 mg DRSP - End of Treatment Results73.8

[back to top]

Number of Subjects With Abnormal Vital Signs

Vital signs included sitting systolic and diastolic blood pressures, and heart rate. (NCT02817828)
Timeframe: From screening to end of treatment (12 months)

InterventionParticipants (Count of Participants)
15 mg E4/3 mg DRSP15

[back to top]

Number of Subjects With Abnormal Laboratory Assessment Results

Laboratory assessment included blood hematology, biochemistry, and lipids (NCT02817828)
Timeframe: From screening to end of treatment (12 months)

InterventionParticipants (Count of Participants)
15 mg E4/3 mg DRSP55

[back to top]

The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening

On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred. (NCT02817828)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionMethod failure Pearl Index (Number)
15 mg E4/3 mg DRSP0.29

[back to top]

Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction Over the Past Week

"The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good.~A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score).~In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate satisfaction with medicine and overall life satisfaction over the past week." (NCT02817828)
Timeframe: Baseline and Cycle 13 (1 cycle = 28 days)

,
InterventionUnits on a scale (Mean)
Satisfaction with medicineOverall life statisfaction over the past week
15 mg E4/3 mg DRSP - Baseline Results4.04.0
15 mg E4/3 mg DRSP - End of Treatment Results4.04.0

[back to top]

Number of Unscheduled Spotting Days Per Cycle

Unscheduled spotting is defined as any spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting. (NCT02817841)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionDays (Mean)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP1.00.60.60.50.50.50.50.40.50.40.40.4

[back to top]

Number of Unscheduled Bleeding Days Per Cycle

Unscheduled bleeding is defined as any bleeding that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting. (NCT02817841)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionDays (Mean)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP0.40.30.40.30.30.30.30.20.30.30.20.2

[back to top]

Number of Subjects With Unscheduled Bleeding/Spotting Episodes

Unscheduled bleeding/spotting is defined as any bleeding/spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding. (NCT02817841)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP532345337302238253229204221184159175

[back to top]

Number of Subjects With Bleeding and/or Spotting Episodes by Reference Period

Bleeding data were analysed by 91-day reference period. There were 4 RPs: Reference Period 1 = Day 1 to Day 91; Reference Period 2 = Day 92 to Day 182; Reference Period 3 = Day 183 to Day 273; and Reference Period 4 = Day 274 to Day 364. (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
Reference Period 1Reference Period 2Reference Period 3Reference Period 4
15 mg E4/3 mg DRSP - RP11,2491,098982914

[back to top]

Number of Subjects With Absence of Scheduled Bleeding and/or Spotting

Scheduled bleeding/spotting is defined as any bleeding/spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle. (NCT02817841)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP230254274233209225191183180137136134

[back to top]

Number of Participants With Clinically Abnormal Gynecological Examination Results

"Gynecological examinations included breast examination (performed by palpation) and assessment of the adnexa, cervix, uterus, vagina, and external genitalia.~When reporting the results, the use of the Abnormal category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the Normal category included Abnormal results that were not clinically significant, as well as no findings." (NCT02817841)
Timeframe: Baseline and end of treatment (Cycle 13 with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
Breast -Baseline72586575Breast - EOT72586575Adnexa - Baseline72586575Adnexa - EOT72586575Cervix- Baseline72586575Cervix - EOT72586575Uterus - Baseline72586575Uterus - EOT72586575Vagina - Baseline72586575Vagina - EOT72586575External genitalia - Baseline72586575External genitalia - EOT72586575
AbnormalNormalNot done
15 mg E4/3 mg DRSP1,857
15 mg E4/3 mg DRSP6
15 mg E4/3 mg DRSP1
15 mg E4/3 mg DRSP1,387
15 mg E4/3 mg DRSP16
15 mg E4/3 mg DRSP11
15 mg E4/3 mg DRSP1,404
15 mg E4/3 mg DRSP1,862
15 mg E4/3 mg DRSP2
15 mg E4/3 mg DRSP1,397
15 mg E4/3 mg DRSP5
15 mg E4/3 mg DRSP12
15 mg E4/3 mg DRSP1,861
15 mg E4/3 mg DRSP3
15 mg E4/3 mg DRSP0
15 mg E4/3 mg DRSP1,402
15 mg E4/3 mg DRSP7
15 mg E4/3 mg DRSP1,841
15 mg E4/3 mg DRSP23
15 mg E4/3 mg DRSP1,386
15 mg E4/3 mg DRSP22
15 mg E4/3 mg DRSP1,860
15 mg E4/3 mg DRSP4
15 mg E4/3 mg DRSP1,398
15 mg E4/3 mg DRSP10

[back to top]

Mean Number of Bleeding and Spotting Days by Reference Period

Bleeding data were analysed by 91-day reference period (RP). There were 4 RPs: Reference Period 1 = Day 1 to Day 91; Reference Period 2 = Day 92 to Day 182; Reference Period 3 = Day 183 to Day 273; and Reference Period 4 = Day 274 to Day 364. (NCT02817841)
Timeframe: up to 12 months (13 cycles)

InterventionDays (Mean)
Reference Period 1Reference Period 2Reference Period 3Reference Period 4
15 mg E4/3 mg DRSP3.63.33.33.9

[back to top]

Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)

The MDQ is a standard method for measuring cyclical perimenstrual symptoms. The participants rated common symptoms and feelings associated with menstruation using the following scale: 0 (no experience of symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong),and 4 (present, severe) observed during pre-menstrual (4 days before menstruation), menstrual (most recent flow) and intermenstrual (remainder of the cycle) phases. Reported values are values at Cycle 13 minus values at Baseline. An overall positive change from baseline represents an increase in symptom or feeling severity. (NCT02817841)
Timeframe: Baseline and end of treatment (Cycle 13 with 1 cycle = 28 days)

,,
Interventionunits on a scale (Mean)
PainWater retentionAutonomic reactionsNegative affectImpaired concentrationBehaviour changeArousalControl
15 mg E4/3 mg DRSP - Intermenstrual Phase-0.3-0.10.0-0.10.0-0.0-0.20.1
15 mg E4/3 mg DRSP - Menstrual Phase-0.6-0.20.1-0.3-0.1-0.0-0.20.1
15 mg E4/3 mg DRSP - Premenstrual Phase-0.1-0.20.0-0.4-0.1-0.0-0.20.1

[back to top]

The Number of On-treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (16-50 Years)

"On-treatment pregnancies are pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 7 days after the last intake of investigational product (whether active or inactive tablet). The method failure Pearl Index, defined as the number of pregnancies as a result of method failure per 100 women-years of treatment, was calculated as follow: (1300*number of on-treatment pregnancies as a result of method failure)/number of women 28-day equivalent cycles of treatment. Pregnancies due to user failure were excluded from the numerator. User failure pregnancies were pregnancies that occurred when the subject did not take the investigational product correctly.~At-risk-cycle was defined as cycle in which no other methods of birth control (including condoms and emergency contraception) were used by the subject and during which the subject confirmed that sexual intercourse had occurred." (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionMethod failure Pearl Index (Number)
15 mg E4/3 mg DRSP1.44

[back to top]

The Number of On-treatment Pregnancies (With +7-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 16 to 35 Years, Inclusive, at the Time of Screening

"On-treatment pregnancies are pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 7 days after the last intake of investigational product (whether active or inactive tablet). The method failure Pearl Index, defined as the number of pregnancies as a result of method failure per 100 women-years of treatment, was calculated as follow: (1300*number of on-treatment pregnancies as a result of method failure)/number of women 28-day equivalent cycles of treatment. Pregnancies due to user failure were excluded from the numerator. User failure pregnancies were pregnancies that occurred when the subject did not take the investigational product correctly.~At-risk-cycle was defined as cycle in which no other methods of birth control (including condoms and emergency contraception) were used by the subject and during which the subject confirmed that sexual intercourse had occurred." (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionMethod failure Pearl Index (Number)
15 mg E4/3 mg DRSP1.43

[back to top]

The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (16-50 Years)

"On-treatment pregnancies are pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 7 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. Only at-risk cycles were included in the denominator of the Pearl Index calculation, unless a conception occurred during a cycle.~At-risk-cycle was defined as cycle in which no other methods of birth control (including condoms and emergency contraception) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred." (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionPearl Index (Number)
15 mg E4/3 mg DRSP2.52

[back to top]

The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 16 to 35 Years, Inclusive, at the Time of Screening

"On-treatment pregnancies are pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 7 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. Only at-risk cycles were included in the denominator of the Pearl Index calculation, unless a conception occurred during a cycle.~At-risk-cycle was defined as cycle in which no other methods of birth control (including condoms and emergency contraception) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred." (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionPearl Index (Number)
15 mg E4/3 mg DRSP2.65

[back to top]

Rate of Pregnancy (Life-table Analysis) in Participants Aged 16 to 50 Years

"The life-table analysis evaluates the cumulative probability of pregnancy over 13 cycles. Cumulative Rate and 95% confidence interval (CI) are from Kaplan-Meier estimation. Only on-treatment pregnancies are included.~On-treatment pregnancy is a pregnancy with an estimated date of conception after the date of the first dose of study medication to 7 days after the last dose of study medication (regardless of whether the last dose is an active or inactive tablet) inclusive." (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

Interventionpercentage of participants (Number)
15 mg E4/3 mg DRSP2.00

[back to top]

Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction and Contentment Over the Past Week

"The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. The last two items - item 15 rating satisfaction with medicine and item 16 rating overall life satisfaction over the past week are two global items that are scored individually. For both items, a higher score is associated with a better outcome." (NCT02817841)
Timeframe: Baseline and end of treatment (Cycle 13 with 1 cycle = 28 days)

InterventionUnits on a scale (Mean)
Satisfaction with medicine - BaselineSatisfaction with medicine - EOTOverall life satisfaction - BaselineOverall life satisfaction - EOT
15 mg E4/3 mg DRSP4.24.14.14.1

[back to top]

Number of Participants With Clinically Abnormal Physical Examination Results

"Physical examinations included an evaluation of body as a whole, skin, head, eyes, ears, nose, and throat, neck, cardiovascular, respiratory, musculoskeletal, neurologic, lymphatic/thyroid, abdomen. When reporting the results of the physical examination, the use of the Abnormal category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the Normal category included Abnormal results that were not clinically significant, as well as no findings." (NCT02817841)
Timeframe: Baseline and end of treatment (Cycle 13 with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
Body as a whole -Baseline72586575Body as a whole - EOT72586575Skin - Baseline72586575Skin - EOT72586575Head, Eyes, Ears, Nose and Throat - Baseline72586575Head, Eyes, Ears, Nose - EOT72586575Neck - Baseline72586575Neck - EOT72586575Cardiovascular - Baseline72586575Cardiovascular - EOT72586575Respiratory - Baseline72586575Respiratory - EOT72586575Musculoskeletal - Baseline72586575Musculoskeletal - EOT72586575Neurologic - Baseline72586575Neurologic - EOT72586575Lymphatic/Thyroid - Baseline72586575Lymphatic/Thyroid - EOT72586575Abdomen - Baseline72586575Abdomen - EOT72586575Additional findings -Baseline72586575Additional findings - EOT72586575
NormalAbnormalNot done
15 mg E4/3 mg DRSP1,838
15 mg E4/3 mg DRSP25
15 mg E4/3 mg DRSP1,412
15 mg E4/3 mg DRSP18
15 mg E4/3 mg DRSP1,856
15 mg E4/3 mg DRSP7
15 mg E4/3 mg DRSP1,424
15 mg E4/3 mg DRSP1,852
15 mg E4/3 mg DRSP10
15 mg E4/3 mg DRSP1,429
15 mg E4/3 mg DRSP1,862
15 mg E4/3 mg DRSP1,861
15 mg E4/3 mg DRSP3
15 mg E4/3 mg DRSP0
15 mg E4/3 mg DRSP1,428
15 mg E4/3 mg DRSP2
15 mg E4/3 mg DRSP6
15 mg E4/3 mg DRSP1,851
15 mg E4/3 mg DRSP12
15 mg E4/3 mg DRSP1,423
15 mg E4/3 mg DRSP1
15 mg E4/3 mg DRSP8
15 mg E4/3 mg DRSP1,860
15 mg E4/3 mg DRSP4
15 mg E4/3 mg DRSP1,431
15 mg E4/3 mg DRSP21
15 mg E4/3 mg DRSP30

[back to top]

Rate of Pregnancy (Life-table Analysis) in Participants Aged 16 to 35 Years

"The life-table analysis evaluates the cumulative probability of pregnancy over 13 cycles. Cumulative Rate and 95% CI are from Kaplan-Meier estimation. Only on-treatment pregnancies are included.~On-treatment pregnancy is a pregnancy with an estimated date of conception after the date of the first dose of study medication to 7 days after the last dose of study medication (regardless of whether the last dose is an active or inactive tablet) inclusive." (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

Interventionpercentage of participants (Number)
15 mg E4/3 mg DRSP2.06

[back to top]

Number of Participants With Clinically Significant out-of Range Hematology Results

(NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
15 mg E4/3 mg DRSP8

[back to top]

Number of Participants With Clinically Significant out-of Range Serum Chemistry and Lipid Profile Results

(NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
15 mg E4/3 mg DRSP21

[back to top]

Number of Subjects With Clinically Abnormal Vital Signs

Vital signs included sitting systolic and diastolic blood pressures, and heart rate. All abnormal findings in vital signs that were considered by the Investigator to be clinically significant were recorded as adverse events. (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
15 mg E4/3 mg DRSP10

[back to top]

Number of Subjects With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability.

A treatment-emergent adverse event (TEAE) was defined as any AE not present prior to the initiation of the treatment or any event already present that worsened in either intensity or frequency following exposure to the treatment. Since the starting point for adverse event (AE) collection was the signing of the informed consent, not the start of the investigational product, the AEs recorded prior to first investigational product administration were designated as AEs while those that occurred or worsened after the initiation of the investigational product were designated as TEAEs. (NCT02817841)
Timeframe: Up to 12 months (13 cycles with 1 cycle = 28 days)

InterventionParticipants (Count of Participants)
15 mg E4/3 mg DRSP1,002

[back to top]

Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)

The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). The minimum raw is 14 and maximum raw score is 70. Thus the formula for % maximum score can be written as (raw score -14)/56. A higher percentage maximum score indicates a higher life enjoyment and satisfaction. (NCT02817841)
Timeframe: Baseline and end of treatment (Cycle 13 with 1 cycle = 28 days)

InterventionPercentage maximum score on a scale (Mean)
BaselineEOT
15 mg E4/3 mg DRSP75.875.4

[back to top]

Number of Scheduled Bleeding and/or Spotting Days Per Cycle

Scheduled bleeding/spotting is defined as any bleeding/spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle. (NCT02817841)
Timeframe: Up to 11 months (12 cycles with 1 cycle = 28 days)

InterventionDays (Mean)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
15 mg E4/3 mg DRSP6.14.74.74.84.44.44.54.54.44.34.34.3

[back to top]

Change From Pre-intervention to Intervention Endpoint in Behavioral Inhibition Subscale Score

The Behavioral Inhibition/Behavioral Activation questionnaire will be used to assess behavioural inhibition (BI). The minimum score on the BI subscale is 7, maximum 28. Greater scores indicate greater BI. Change is defined as the average change in BI from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC1.43

[back to top]

Change From Pre-intervention to Intervention Endpoint in Binge Eating Sum Score

"Binge eating will be measured using the 8-item binge eating subscale of the Eating Pathology Symptoms Inventory (EPSI), which measures features of binge eating (e.g., consumption of large quantities of food, mindless eating) on a 5-point Likert scale from never to very often. The EPSI scale is designed to assess behavior over the past 28 days. Items are summed for a scale score ranging from 0-32. Higher scores indicate more frequent experiences with binge eating behavior. Change is defined as the average change in the binge eating scale score from pre-intervention to intervention." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC-6.60

[back to top]

Change From Pre-intervention to Intervention Endpoint in Delay Discounting Parameter k

The Monetary Choice Questionnaire will be used to measure delay discounting. Participants will be asked to make a series of hypothetical choices between small, sooner (impulsive) vs. larger, later (self controlled) hypothetical monetary outcomes. k is a hyperbolic function with larger k values indicating more valuation of a larger delayed reward and smaller values indicating preference for more immediate, smaller rewards (more impulsivity). k can range from 0 to .25 with scores of .25 indicating complete valuation of the immediate reward and 0 indicating complete valuation of the larger, delayed reward. Change is defined as the average change in k from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionk value (Mean)
Continuous OC.01

[back to top]

Change From Pre-intervention to Intervention Endpoint in Nucleus Accumbens Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Nucleus Accumbens (NAcc) reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
Continuous OC.0423

[back to top]

Change From Pre-intervention to Intervention Endpoint in Prefrontal Cortex Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Prefrontal cortex reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
Continuous OC.01

[back to top]

Change From Pre-intervention to Intervention Endpoint in Self-reported Reward Sensitivity Subscale Score

Sensitivity to Punishment/Sensitivity to Reward Questionnaire will be used to measure reward sensitivity. The reward sensitivity subscale will be used, which is rated on a true/false scale with scores ranging 0-24. Higher scores indicate more sensitivity to reward. Change is defined as the average change in reward sensitivity from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC1.60

[back to top]

Change From Pre-intervention to Intervention Endpoint in Weekly Average Binge-eating Frequency

Binge eating frequency is based on a weekly diary of self-reported binge eating frequency. Participants were asked how many times during the past week they had a binge eating episode. Scores can range from 0 to infinity as frequency is self-reported as the number of binge eating episodes in the previous week. Higher scores indicate more episodes of binge eating. Change is defined as the average change in self-reported binge eating frequency from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionepisodes/week (Mean)
Continuous OC-0.43

[back to top]

Change From Pre-intervention to Intervention Endpoint in Dorsal Striatum Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Dorsal striatum reactivity (defined as caudate signal intensity and putamen signal intensity) to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
CaudatePutamen
Continuous OC-.012.02

[back to top]